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Chapter‐I                                                         General Introduction 
GENERAL INTRODUCTION 
             Drug discovery has its beginning the root of mankind 1. 
             Medicinal Chemistry is an interdisciplinary science that by its very nature 
encompasses the sciences of chemistry, biochemistry, physiology, pharmacology and 
molecular modeling. It has been stated that medicinal chemistry concern the discovery, the 
development, the identification and interpretation of the mode of action of biologically active 
compounds at molecular level 2.  
              Medicinal chemistry involves the identification, synthesis, and development of new 
chemical entities suitable for therapeutic use. It also includes the study of existing drugs, their 
biological properties and their quantitative structure activity relationships (QSAR). 
              Early drug design started with elucidation of the structure of the natural products, 
followed by selective changes in the molecule. To improve therapeutic properties is to 
identify that portion of a natural molecule responsible for its biological activity and synthesis 
new molecules that are based on it.  
              The synthetic compounds Offered an Opportunities to medicinal screening. The 
inventions of new lead molecules are used to design effective and safe drugs and also to 
reduce drug toxicities 3. 
              So, Medicinal Chemistry plays a vital role in identification of lead compounds and 
through molecular modification new compounds could be synthesized and thereby it helps in 
the eradication of fatal disease in human being1.  
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                                     OUTLOOK OF ISATIN 
             Isatin is a resourceful endogenous heterocyclic molecule identified in human being 
and rat tissues4. Isatin, chemically known as 1H-Indole-2, 3-dione, has become a popular 
topic due to its various uses. 
             Isatin was first obtained by Erdman and Laurent in 1841 as a product from the 
oxidation of indigo by nitric acid and chromic acids. The synthetic Versatility of isatin has 
led to the extensive use of this compound in Organic Synthesis5.   
             The chemistry of Isatin and its derivatives is particularly interesting because of their 
potential application in medicinal chemistry. Compounds of the isatin series are 
multifunctional compounds from which it is possible to synthesis an enormous number of 
assorted organic compounds. 
             The presence of several reaction centers in isatin and its derivatives makes it possible 
to bring these compounds into various types of reactions. Thus, keto group at position 2 and 
particularly, at position 3 can enter into addition at the c-o bond and into condensation with 
release of water. 
             Through the NH group compounds of the isatin series are capable of entering into N-
alkylation and N-acylation and into the Mannich and Michael reactions6. The synthetic 
versatility of Isatin has stemmed from the interest in the biological and pharmacological 
properties of its derivatives.  
            Schiff and Mannich bases of Isatin derivatives are reported to show variety of 
biological activities like antibacterial, antifungal, anticonvulsant, anti HIV, anti depressant 
and anti inflammatory activities7. 
            All the synthesized isatin derivatives were evaluated for their antimicrobial, analgesic 
and ulcerogenic activities. 
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Chapter‐I                                                                            Literature Review                        
                                                LITERATURE REVIEW 
1. Rajendra et.al., synthesized 3-Aryl glycyl hydrazono -2-indolinone derivatives as  
            amoebicidal and antibacterial agents.8 
                       
N
R1
O
N NH
O
CH2 NH R2
R1 = -H, -CH3, XN-CH2 Where X = O, CH2
R2  = -H, -Cl, -Br, -CH3, -OCH3  
 
2     M. Sarangapani et.al., synthesized 1-(N,N – disubstituted amino) methyl -3-imino –  
(2-   phenyl -3,4 –dihydro -4-oxo-quinazolin-3-yl) indol-2-one.9                                             
R = -H, -CH3, Where X = O, CH2
R1
R
N
CH2 R1
O
N N
N
H
Ph
O
-Br
= -N(CH2OH)2, -N(C6H11)2, N X
Ph= Phenyl
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3 S.K. Sridhar et.al., synthesized N- Mannich bases of 10- H- indolo (3,2, -b) 
Quinoxalines. 10 
               
                        
N
NN
R1
CH2 R2
R1= -H, -Cl, -CH3
R2= -N(CH3)2, -N(C2H5)2, XN
where X= O,CH2
 
 
4.      Freddy H. Havaldar et.al., synthesized 1-(substituted amino methyl)-3-(3’-bromo-          
         4’methoxy Benzoyl hydrazono) indolin-2- one .11 
           
                          
H3CO CONHN
Br
N
CH2 R
O
R= NH NH OCH3 N
CH3
C6H5
XN
, ,
where X=O,CH2
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  5.     A.K.  Pathy et.al., synthesized 1-acetyl-3-(2-acetoxyl-3-substituted propyl)oximino 
           indol- 2-(3H)one.12     
                         
                      
N
Ac
O
NOCH2 CH CH2
OAc
R
R= N N N
CH3
C6H5
, ,
Ac= Acetyl
-N(C6H5)2, , -N(C6H11)2
  
 
 
6.      R.S.  Varma et al., synthesized 1-Heterocyclic amino methyl 3-(4’-acetyl amino-3’-                  
        Chlorobenzoyl hydrazono)-2-indolinone as potential antimycotics.13 
 
 
                         
N
CH2
O
R
R1
R2
NHN C
O
NH C
O
CH3
R= H,-Cl,-Br,-CH3 R1 =H, -Br
R2= N X where X= O, CH2  
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7.  P.Selvam et.al., Synthesized 4-(1-3-disubstituted 2-oxo-1,2 dihydro-indol-3-  
     ylideneamino)  N-[4,6  Dimethyl –pyrimidin-2-yl]-benzene sulphonamides were reported 
     to possess antiviral activity.14 
 
                                          
N
C
O
R
R1
N
O
SO2NH
N
N
CH3
CH3
 
 
                                                        R = H, Cl  
                                                        R1=CH3, C6H5 
 
 
8. Jain and Bansal synthesized heterocyclic derivatives of isatin and studied anticonvulsant 
    activity in  rats.15 
      
                                                        
N
H O
O
COOC2H5
NH2
CH3
H5C6OC
F
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 9.  Pajovhesh et al., synthesized a series of cyclohexane and other cyclic ketone derivatives   
      of  isatin and Screened them for anticonvulsant activity.16 
 
                                     
N
H
O
OH
O
R
 
 
                            R= H, 1-CH2C6H5, 5-Br, 5-Cl, 5-CH3, 5-OCH3, 5-NO2, 6-Cl, 7-CH3,  
                                  4-Cl-7-CH3, 4-Cl-7-OCH3, 5-Cl-7-CH3, 6-Cl-5-OCH3, 6-Cl-7-CH3 
                                      
 
                                     
N
H O
OH
O
R
R1
                
   
                               R= H, 1-CH3, 5-Br, 5-NO2, 4-Cl-7-CH3 
                               R1= 2-methyl cyclohexanone, 2-cyclohexyl cyclohexone, 
                                       3- methyl cyclohexanone 
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10.  Olesen and Kanstrup prepared pyrido[2,3-b] indoles to treat epilepsy, senile dementia  
       and Parkinsonism.17 
 
                                        
N
R6
N R2
R3
R4R5
R7
R8
R1  
                                R 1 = H, C1-6 alkyl (CH3, C2H5, C3H7-C6H13) 
                                R 2 = piperidino, morpholino 
                                R 3 =H, COOH, CN 
                                R 4= H, C1-6 alkyl (CH3, C2H5, C3H7) 
                                R 5-R 8 = H, NO2, NH2 
 
 
11. Karali et.al ., synthesized a series of 3-thiosemicarbazono-2-indolinones and studied 
      anticonvulsant Activity. 18 
              
N O
R1
NHN C
S
R
NH R2
N O
R1
N
R
N
S
R2
O
 
 
                R= H, COCH3               R 1 = H, Br           R 2 = CH3, C2H5, C6H5 
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12. Gursoy and Karali synthesized a series of 3-aryloxyl, arylthioxy acetyl hydrazono-2- 
       indolinones and studied anticonvulsant activity.19 
                      
                           
N
H
O
R N C
O
CH2XR1
 
 
                         X= O, S                      R= H,Br 
                         R 1= C6H5, 3-CH3-C6H4 4, 5 diphenyl –(1-H)- imidazol-2-yl 
 
 
13.  Ghaney and EI- Helbyl synthesized 1,3 dioxo –n-phenyl -2H iso indol-2-acetamide and 
       studied  anticonvulsant activity.20 
 
 
                              
N
R
O
O
CH2 C
O
NH
R1 R2
R3
 
                          
                           R 1= H, CH3, Halogens, OH 
                           R 2= H, CH3, Br 
                           R 3= H, CH3, Br, Cl 
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14. S.N Pandeya et al., synthesized p- nitrophenyl substituted semicarbazone and their  
       anticonvulsant activity was screened against Maximal Electric Shock test.21 
 
                     
N
H
R
N
O
NH
C O
NHO2N
N
R2
N
O
NH
C O
NH
R1
R
 
                    
                   R= H, Cl, NO2                                                              R = 2-Cl, 3-Cl, 4-Br, 4-NO2, 4- SO2NH2 
                                                                                    R 1= CH3, COCH3     
                                                                                    R 2= H, NO2 
 
15. S.N Pandeya et al., synthesized halo substituted isatin semicarbazones and screened for  
       anticonvulsant activity.22 
                                    
                                 
N
NNHC=OR1
O
R2
R
 
                   R = H, 4-Cl, 5-Cl, 6-Cl 
                   R 1= CH2O-C6H5, 1-(CH2O)-(4-Br)-C6H4 
                   R 2= COCH3, CH2C6H5      
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16.  S.N Pandeya et al., synthesized various Schiff bases of isatin derivatives and screened  
       them  for anticonvulsant activity.23 
 
                                         
N
N
O
R1
R R2
  
                    R = Br, NO2 
                    R 1= CH3, COCH3 
                    R 2=NO2, COOH, OCH3, Cl, F 
 
17. Varma and Nobles investigated various Isatin –N-Mannich bases of isatin-3 
      thiosemicarbazone derivatives against viral, fungal and antibacterial organisms.24 
 
                                             
N
NNH
O
CH2
R C
S
NH2
R1  
 
                          R= H, CH3, Br 
                          
R1= N , N O , N
CH3
N(C2H5)2  
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18.  V.Ravichandran et.al, synthesized mannich bases of isatin and its derivatives with 
       2-[(2, 6 dichloro phenyl)amino] phenyl acetic acid.25       
                   
               
N
R
O
N
HOOCH2C
Cl
Cl
R= ClNH2 SO2NH2NH2 COOHNH2, ,
 
 
 
19.  Periyasamy Selvam et.al, synthesized 4-[(1, 2-dihydro-2-oxo-3H-indol-3-ylidene) 
       amino] N-(4, 6-dimethyl-2-pyridin-2-yl)benzene sulphonamide and its derivatives as  
       antiviral agents.26 
                             
N
N
O
S
O
O
NH
N
N
R
R1  
 
                     R= Br, Cl, F, H, CH3 
                     R1= H, COCH3 
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20. Vijay Anandhi M., et.al., synthesized 1-(5-substituted-2-oxo indolin-3-ylidine)-4      
      (substituted Pyridine-2yl) thiosemicarbazide as antimicrobial agents.27 
 
                         
N
NNHCSNH
O
R
1
H
N
R1 R2
R3
R4
 
                        R1 = F, Cl, Br,      R1 = H, CH3,    R2 = H, CH3,     R3 = H, Cl       R4 = H,CH3 
 
 
 
21.  Okay Bekirkan  et.al., synthesized Schiff and  Mannich bases of Isatin derivatives with 
        4 amino-4,5 dihydro-1,4-1,2,4-triazole-5-ones.28 
 
                                                
N
N
N
N
N N
H
O
R
            
                                                   R = 2-F, 4-F        X = H, Cl 
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22. Ankur Patel et.al, synthesized some new Isatin derivatives as antimicrobial agents.29 
 
                            
N
H
N NH
O N
N
R
 
 
             R = H, 5-Cl, 5-F, 5-Br, 4-Cl, 5-CH3,    
 
23.  Sivakumar Smitha et.al, synthesized N-acetyl methyl isatin derivatives as  
       anticonvulsant  and Sedative-hypnotic agents.30  
 
                                
N O
N NH
NH
O
R
1
R X
 
 
                 R = H, 5-Br, 5-NO2        
                 X = 4-Cl, 4-NO2, 2-Cl, 4-SO2NH2        
                 R1 = COCH3, CH3 
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24.   Surendranath Pandeya et.al, synthesisized Isatin semicarbazones as novel  
        Anticonvulsants.31 
 
                                  
N O
N NH
R1
OH
R2
R
 
             R = 4-Cl, 5-Cl, 6-Cl, H          
             R1 = H, COCH3, COC6H5              
             R2 = 2-Chloro phenyl amino, 4-Nitro phenyl amino, 4-Bromo phenyl amino  
 
25.    Seshaiah Krishnan Sridhar et.al., synthesized Hydrazones, Schiff and Mannich bases 
         of Isatin derivatives.32 
                                          
N O
N R1
R1
R
           
                  R = H, Cl, Br  ,                  R2 =   H,   -CH2-N(C6H5)2 
                   R1 =  , 
Br
, 
NH
, 
CH3
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26.   Prince .P. Sharma et al., synthesized some Novel Isatin Schiff’s bases as  
        anticonvulsant agents.33 
 
                               
N
S N
R
NH
O
 
 
        R =   H,  N(CH3)2,  Cl,  OCH3,  Br,  CH3,  C2H5,  OC2H5,  OC2H5,  NO2,  F 
 
 
27.   P.Selvam et al., synthesized Novel Isatin Sulphonamides as antiHIV agents.34 
 
                            
N
R1
R
N S
O
O
NH R2
O
 
 
             R =  H,  CH3,  Cl,  Br   
             R1 =  H,  CH3,  COCH    
             R2 =  H,  4,5 Dimethyl-2-isoxazolyl,     
                       4,6 dimethyl-2-pyrimidinyl 
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28.  Manjusha Verma et.al., synthesized Schiff bases Isatin derivatives  as anticonvulsant 
       agents.35 
                             
N
R1
R
N
O
R2
 
           R = Br, NO2                   
           R1 = CH3, COCH3             
           R2 = NO2, COOH, OCH3,  Cl,  F. 
 
 
29.  Dharmarajan Sriram et.al., synthesized Gatifloxacin derivatives as antimycobacterial 
       agents.36 
 
                                
N
R R1
O
N
N
N
H
F
O
OH
O
  
            R =  H,  F,  Cl,  CH3. 
           =R1 O N NH
O
NH2 N NH
S
NH2, ,  ,  
             
N
O
NHN
   ,
N SO2NH
N
N    
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30. Varma et.al., synthesized  isatin –N- mannich bases and screened  for antimicrobial  
       activity.37 
                                                
N O
O
CH2 R
1
R
                                   
                                         R = H, Br,       R1= - N(C2H5)    
                                         
N= , N O
 
 
 
31. Kupinic etal., synthesized a congenial series of isatin –N- Mannich bases and evaluated  
      their  antimicrobial activity.38 
                                                
R
3
N
CH2 R
1
R
2
O
 
 
            R1=N(C2H4OH)2 , N(C2H4Cl)2,  
                
= N , N O
 
            R2= O, NNHCOCH3, NNHCH3,  
                    NNHCSNH2, NNHCOOH 
            R3= H , NO2 
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 32. Pandeya and Sriram synthesized isatin and its derivatives with trimethoprim  and  their  
       N- Mannich Bases.39 
                                           
N
CH2 R
1
N
O
N
N
CH2
OCH3
OCH3
OCH3
R
 
 
              R = H , CH3 
                  R1= -N(CH3)2 , -N(C2H5)2 ,-morpholino, -piperidino, -pyrrolidino, - 
                      sulphamethoxazolo 
 
33. Pandeya et.al., synthesized Schiff bases of isatin with sulfodoxine.40 
                      
                      
N
CH2 R
1
N
O
SO2NH N
N
H3CO OCH3
R
 
      
             R = H , CH3 
             R1= N(CH3)2 , N(C2H5)2, 1-piperidyl, 1-pyrrolidinyl, 4-morpholinyl ,  
                     pyrimethamine. 
 
 
20 
 
Chapter‐I                                                                            Literature Review 
 
34. Pandeya synthesized isatin N-Mannich bases of Ciprofloxacin and Lomefloxacin.41 
                              
                          
N
CH2
O
O
R
N N
R
1 O
R
2 R
3
COOHF
 
 
              R = R1 = H, CH3 
                     R2=H, F                                     
              R3= C2H5 , Cyclopropyl 
 
35. Teitzs et.al. , synthesized substituted Isatin thiosemicarbazone and screened for antiviral 
      activity.42        
 
                            
N
R
N
O
NH
S
R
1
 
 
              R = -CH3 , -CH2-CH=CH2 
              R1= -N(C2H5)2, -N(CH2CH=CH2)2 
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36. Webber et al., reported the design, synthesis and biological evaluation of novel Isatin 
      derivatives.43 
                                
N
R
1
O
O
R
 
 
                    R= H, Cl, NO2, COOH, COCH3, CN, CONH2, CONHCH3, CON(CH3)2 ,  
                          CSNH2COCH3, OSCH3   
                    R1= CH3, CH2-CH=CHC6H5, CH(CH2)3, C6H5,CH2C6H5,CH2, CH2-β-naphthyl, 
                           CH2(4-CH3-C6H4), CH2(3,4-(CH3)2-C6H3),CH2(3-OCH3-C6H4), 
                           CH2(3,5 (OCH3)2-C6H3) 
37. F.D. Popp et al., synthesized 3-(o)-nitro phenyl hydrazones of isatin derivatives and 
      screened for  Anticancer activity.44 
       
                           
N
H
O
NH
R
NH
O2N
 
              R = -H, 1-CH3, 1-COCH3, 4-CF3, 5-Br, 5-Cl, 5-F,  5-OCH3, 5-CH3, 5-NO2, 5-SO3H,  
                      7-Cl, 7-CH3, 4Cl-7-OCH3, 6-Cl-5-OCH3, 4-Cl-7-CH3, 4,7-(Cl)2,  5,7-(Cl)2,  
                      4, 7-(CH3)2, 5,7-(CH3)2, 6,7-(CH3)2 
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38.  Eshba and Salama synthesized 5-(2-oxo,3-indolinyl)thiazolidine, 2,4-dione having 
       Position1 and 3 of the Isatin and Thiazolindine rings respectively,substituted by  
       Mannich bases.45 
 
                            
N O
N
CH2 N
CH3
CH3
Br
N
S
O CH2 N
CH3
CH3
 
39.  Varma et.al., synthesized  3[p-(p-alokoxy carbonyl)-phenyl]imino-1-aminomethyl-2   
       indolinones and  Investigated their antitubercular activity against Mycobacterium 
       tuberculosis H37Rv.46 
 
                           
N O
NH
CH2 N X
CONH COOR
 
 
                           X = O, CH2,        
                           R = CH3, C2H5, n-propyl, n-butyl 
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40.  Rajendra S.Varma etal., synthesized 1,3 disubstituted 5-carboxy methyl -2-indolinone  
       as CNS active agents.47 
                          
N O
N
R
1
NH R
2
CH2HOOC
 
            R1= H, CH3, Morpholinylmethyl, piperidino methyl 
            R2= benzoyl, phenyl aminothiocarbonyl, p-(Cl)benzoyl, p-(OH)benzoyl 
41.  Alka pande et al., synthesized 1, 3 disubstituted new indole derivatives as antiviral  
        agents.48 
                         
N O
N
CH2 R1
R NH CO
NO2
NO2
 
             R = CH3, Br 
            R1=  -N(CH3)2,  -N-(C2H5)2,  -N(CH2OH)2,  
 
                 
NN N
CH3
, ,
N O ,
N
C2H5
, N N , N N CH3
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42.  K.Mugilaiah et al., synthesized novel Isatin Mannich bases bearing 1, 8 – naphthyridin  
      Moiety.49 
                            
N N
O
CH2
NO
R
CH2 N X
CONHN
 
                        R= H, CH3, Cl, Br                                          X= CH2, O, N‐CH3 
 
43.  Navneet Agarwal et al., synthesized 4-aryl substituted semicarbazones of some terpenes  
       as Novel anticonvulsants.50 
                                   
N NH C
O
NH R
 
              R= H, Cl, Br, F, CH3, OCH3, NO2  
                                    
C
H
NNH C
O
NH
 
              R= H, Cl, Br, F, CH3, OCH3, NO2 
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44.  S.N Pandeya, synthesized 4-N substituted aryl semicarbazones as anticonvulsant 
       agents.51 
 
                                     
X
N C
y O
NH
NCR
R
3 R
2
R
1
 
                   X= H, Cl, NO2                                 y = -C2H5, -H 
                   R= H, CH3                                       R1= -OH, -H, -Cl 
                   R2= H,OCH3                                   R3= H,-OH,-OCH3, NO2 
 
 
45.  Navneet Agarwal et.al., synthesized 4-substituted semicarbazones of Levulenic acid & 
       evaluated for anticonvulsant activity.52 
 
 
                                      
CH
CH3 CH2CH2COOH
NHCNNH
O
R
 
             
                      R= H, Cl, Br, F, CH3, OCH3, NO2 
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46. Surendra N. Pandeya, Dhamrajan Sriram et al., synthesized norfloxacin Mannich bases  
 
      and Evaluated the antibacterial, antifungal and anti-HIV activities.53 
 
 
                            
                                  
N
O
R
1
N
N
N
F
O O
OH
CH2CH3
R
R= H, Cl, Br
R
1
= N SO2NH
N
N
N SO2NH
N
N
H3CO OCH3
N
N
N SO2NH
OCH3
OCH3
OCH3
NH2  
 
47. Kara L. Vine, Julie M. Locke, Marie Ranson, Stephen G. Pyneb and John B. Bremnerb  
Carry out the In vitro cytotoxicity evaluation of some substituted isatin derivatives.54 
 
N
R1
O
R6
R3
R4
R5
R2
 
R1, R2, R3, R4, R5, R6 = H, CH 
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48. E.G. Mesropyan, G.B. Ambartsumyan, A.A. Avetisyan, M.G. Sargsyan, and A.S. 
galstyan, Synthesis of new isatin aromatic derivatives.55 
 
                                    
N
O
O
CH2
N
O
O
CH2X
N
O
O
X CH2Cl
N
O
O
Me
Me
N
O  
 
49. S.N. Pandeya, D. Sriram, G. Nath, E. DeClercq, Synthesis, antibacterial, antifungal and  
       anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and 
       N-[4-(49-chlorophenyl) thiazol-2-yl] thiosemicarbazide.56 
                          
N
N
O
R
1
R NH
S
S NH
S
N Cl
 
 
                                       
                              
R = H , Cl, Br,
R
1
= H, H, H. CH2 -N (CH3)2 NCH2 N OCH2
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50. Seshaiah Krishnan Sridhar, Surendra N. Pandeya, James P. Stables, Atmakuru Ramesh,             
      Study  the Anticonvulsant activity of hydrazones, Schiff and Mannich bases of isatin    
      derivatives.57 
 
 
                                                 
                                               
N
N
O
R3
R1 R2
 
 
                  R1= H, H, H, H, H, H, H 
 
                  R2= 1-Napthyl, 4- Chloro penyl, 4- Methyl Phenyl, 4- Bromo phenyl 
 
                          4- Methoxy phenyl, Thiosemi carbazino, Phenyl Hydrazino 
 
                  R3= H, H, H, H, H, H, H 
 
 
 
 
51. Asensio González , Josefina Quirante et al., Synthesis of  Isatin derivatives, a novel class   
      of transthyretin fibrillogenesis inhibitors.58 
 
 
                       
N
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1
R
2
N
N
O
R
1
R
2 R
3
 
 
 
                         R1= H, CH3,H, CH3, H, CH3 
 
                         R2= H, H, H, H, I 
 
                         R3= H, H, H, H, H, CH3. 
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52. Dharmarajan Sriram, PerumalYogeeswari, Gayatri Gopal, Synthesis, anti-HIV and  
      antitubercular activities of lamivudine prodrugs.59 
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N
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O
S
OH
R
 
 
 
                         R= H, Cl, F 
 
 
                           
R1= 
N
O O
OH
C2H5
N
N
F
N
O O
OH
C2H5
N
N
F
F3C
N
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OH
N
N
N
O O
OH
N
N
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OBJECTIVE OF THE PRESENT WORK 
 
 Based on the literature review, Isatin nucleus has attracted the attention of medicinal 
chemists due to the wide range of biological activities. 
               Basic Structure of Isatin 5, 61 
                                                       
N
H
O
O
1
2
3
4
5
6
7
 
                                                                   Fig-1 
 
Structural Modifications involving variations in the nature of groups in Keto position 
(C=O) have led to a larger number of derivatives by Schiff’s Reaction that are biologically 
active. 
Most of the Isatin derivatives having substitutions at C-3 and C-1 positions having 
wide range of biological activities6 (Fig-1) 
So, in this present study I aimed to synthesis some Novel Schiff and Mannich bases of 
isatin derivatives and screened for its Anti Microbial, Analgesic and Ulcerogenic activities. 
Schiff Bases can be prepared by using p-Nitro aniline, PABA, p-Bromo aniline and 
Sulphanilamide. Mannich base can be prepared by using Ciprofloxacin. 
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The objective of the present work can be summarized as follows. 
I. Synthesis 
 
1. Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4'- nitro 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
 
                                  
N
O
N
+
O
-
O
N
NO2
N
N
N
F
O O
OH
 
 
 
2. Synthesis of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[ 5'nitro-3'-[(4'-carboxy 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
 
 
                             
N
O
N
+
O
-
O
N
COOH
N
N
N
F
O O
OH
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3. Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4'-bromo 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
                           
N
O
N
Br
N
N
N
F
O O
OH
N
+
O
-
O
 
4. Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4' 
sulphamido phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic 
acid. 
                                         
N
O
N
SO2NH2
N
N
N
F
O O
OH
N
+
O
-
O
 
5. Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5' chloro -3'-[(4'- nitro 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid.                                  
                                 
N
O
N
NO2
N
N
N
F
O O
OH
Cl
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6. Synthesis of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[ 5'chloro-3'-[(4'-carboxy 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
 
                                   
N
O
Cl N
COOH
N
N
N
F
O O
OH
 
7. Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro-3'-[(4'-bromo 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid                            
N
O
Cl N
Br
N
N
N
F
O O
OH
 
 
8. Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro-3'-[(4' 
sulphamido phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic 
acid. 
                              
N
O
Cl N
SO2NH2
N
N
N
F
O O
OH
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9. Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-nitro phenyl)-
imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
                                              
N
O
N
NO2
N
N
N
F
O O
OH
 
10. Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-carboxy phenyl)-
imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
 
                                      
N
O
N
COOH
N
N
N
F
O O
OH
 
 
11. Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-bromo phenyl)-
imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
                                                    
N
O
N
Br
N
N
N
F
O O
OH
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12. Synthesis of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[3'-[(4'-Sulphamido 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
                                              
N
O
N
SO2NH2
N
N
N
F
O O
OH
 
 
II. Characterization of the synthesized compounds by various analytical 
techniques like Melting Point, Thin Layer Chromatography, Infra Red Spectra 
and Nuclear Magnetic Resonance Studies. 
 
III. A) Screening the synthesized compounds for Anti-Microbial Activity against 
the Micro Organisms such as Staphylococcus aureus, Streptococcus pyogenes, 
Escherichia coli, Klebsilla aerogenes and the fungi Candida albicans by Cup 
and Plate method. 
 
B) Evaluation of Analgesic activity for the synthesized compounds in mice 
using Diclofenac Sodium as standard drug by Acetic acid Induced Writhing 
Method. 
 
C) Evaluation of Ulcerogenic Index for the synthesized compounds in Albino 
rats. 
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GENERAL SCHEME OF REACTION 
 
Synthesis of Schiff’s bases of isatin: 23, 63 
 
N
H
O
O
R
+
Reflux for 4 hours
C2H5OH
CH3COOH
N
H
O
N
R1
R
Step - I:
(PH 4.5)
Isatin
R1NH2
Compounds having primary amino group
Schiff's Base of Isatin  
 
                              R = NO2, Cl, H 
 
                             
R1 NO2
COOH
Br
SO2NH2
=
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Synthesis of Mannich Bases of Isatin: 52, 60, 62, 63, 64 
 
 
N
H
O
N
R1
R
+
N
COOH
O
F
N
NH
Mannich Reactions
HCHO
(37 to 41% Formalin)
N
O
N
N
N
N
F
O O
OH
R1
R
Schiff's Bases of Isatin Ciprofloxacin
Schiff's and Mannich Bases of Isatin
Step - II:
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SYNTHESIS 
 
I) SYNTHESIS OF SCHIFF BASE23 
Step-I: 
 
            Synthesis of 5-nitro-3-[(4-nitrophenyl) imino]-1, 3-dihydro-2H-indol-2-one. 
 
 
 
            CHEMICALS REQUIRED 
                           
1) 5-Nitro Isatin              -  0.01 mol  
2) p-Nitro aniline           -  0.01 mol 
3) Ethanol                       -  20 ml 
4) Glacial Acetic acid     - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of 5- Nitro isatin (0.01 mol) and p-Nitro aniline (0.01 
mol) were added into 20 ml of absolute ethanol containing a few drops of glacial 
acetic acid in a 250-ml round bottom flask. The reaction mixture was refluxed for half 
an hour and then checked for completion by TLC. The solvent was stripped off and 
the product was recrystallized from ethanol. 
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        SYNTHESIS OF 5-NITRO-3-[(4-NITROPHENYL) IMINO]-1,3-DIHYDRO-2H-    
        INDOL-2-ONE: 
 
        
N
H
O
O
N
+
O
-
O +
NH2
NO2
5-nitro-1H-indole-2,3-dione
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
+
O
-
O
N
NO2
5-nitro-3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one
4-nitroaniline
Step - I:
(PH 4.5)
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       SYNTHESIS OF MANNICH BASE 52  
 
      Step: 2 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4'- 
nitro   phenyl) - imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline 
carboxylic acid. 
 
CHEMICALS REQUIRED 
 
1) 5-nitro-3-[(4-nitrophenyl) imino]-1,3-dihydro-2H-indol-2-one - 0.0025 mol 
2) Ciprofloxacin                                                                               - 0.0025 mol 
3) Glacial Acetic acid                                                                       - 20 ml 
4) 37% Formalin                                                                              -  1 ml 
 
 
 
              PROCEDURE 
 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
(20 ml), was added 5-nitro-3-[(4-nitrophenyl) imino]-1,3-dihydro-2H-indol-2-one 
(0.0025 mol) and 37% formalin(1 ml). The reaction mixture was refluxed over a 
water bath for 1–3 h. The reaction mixture was concentrated to approximately half of 
the initial volume, and the resulting precipitate was recrystallized from a mixture of 
DMF and water. 
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          SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO-7[[N4-    
         [5'NITRO-3'-[(4'- NITRO   PHENYL) - IMINO-1'-ISATINYL] METHYL] N1 
          PIPERAZINYL]-3-QUINOLINE CARBOXYLIC ACID: 
 
N
H
O
N
+
O
-
O
N
NO2
+
N
COOH
O
F
N
NH
5-nitro-3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one
Ciprofloxacin
Mannich ReactionsHCHO
(37% Formalin)
N
O
N
+
O
-
O
N
NO2
N
N
N
F
O O
OH
Step -II:
Glacial CH3COOH
 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4'- nitro   
phenyl) - imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
 
 
42 
 
 
Chapter‐I I I                                                                                            Synthesis                             
 
 
II)  SYNTHESIS OF SCHIFF BASE23 
Step-I: 
 
Synthesis of 4-[(5-nitro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino] 
benzoic acid 
 
 
            CHEMICALS REQUIRED 
                        
1) 5-Nitro Isatin                       -  0.01 mol  
2) Para Amino Benzoic Acid  -  0.01 mol 
3) Ethanol                                -  20 ml 
4) Glacial Acetic acid              - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of 5- Nitro isatin (0.01 mol) and Para Amino Benzoic 
Acid (0.01 mol) were added into 20 ml of absolute ethanol containing a few drops of 
glacial acetic acid in a 250-ml round bottom flask. The reaction mixture was refluxed 
for half an hour and then checked for completion by TLC. The solvent was stripped 
off and the product was recrystallized from ethanol. 
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            SYNTHESIS OF 4-[(5-NITRO-2-OXO-1,2-DIHYDRO-3H INDOL-3-YLIDENE) 
           AMINO] BENZOIC ACID: 
 
                
N
H
O
O
N
+
O
-
O +
NH2
COOH
5-nitro-1H-indole-2,3-dione 4-aminobenzoic acid
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
+
O
-
O
N
COOH
4-[(5-nitro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzoic acid
Step -I:
PH (4.5)
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       SYNTHESIS OF MANNICH BASE 52 
 
       Step: 2 
 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-
[(4'carboxy  phenyl) - imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline 
carboxylic acid. 
 
CHEMICALS REQUIRED 
1) 4-[(5-nitro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene)amino]benzoic acid - 0.0025 
mol 
2) Ciprofloxacin                                                                                             - 0.0025 
mol 
3) Glacial Acetic acid                                                                                     - 20 ml 
4) 37% Formalin                                                                                             -  1 ml 
 
 
 
              PROCEDURE 
 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
(20 ml), was added 4-[(5-nitro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino] 
benzoic acid (0.0025 mol) and 37% formalin (1 ml). The reaction mixture was 
refluxed over a water bath for 1–3 h. The reaction mixture was concentrated to 
approximately half of the initial volume, and the resulting precipitate was 
recrystallized from a mixture of DMF and water. 
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    SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO 
    7[[N4-[5'-NITRO-3'-[(4'-CARBOXY PHENYL)-IMINO-1'-ISATINYL] 
    METHYL] N1-PIPERAZINYL]-3-QUINOLINE CARBOXYLIC ACID: 
N
H
O
N
+
O
-
O
N
COOH
+
N
COOH
O
F
N
NH
Mannich Reactions
HCHO
(37% Formalin)
N
O
N
+
O
-
O
N
COOH
N
N
N
F
O O
OH
Step -I:
4-[(5-nitro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzoic acid
Ciprofloxacin
Glacial CH3COOH
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'-nitro-3'-[(4'-carboxy phenyl)-
imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
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III) SYNTHESIS OF SCHIFF BASE23 
Step-I: 
 
                          Synthesis of 3-[(4-bromophenyl) imino]-5-nitro-1, 3-dihydro-2H-indol-2- 
                          one 
 
 
            CHEMICALS REQUIRED 
                        
1) 5-Nitro Isatin                       -  0.01 mol  
2) p-Bromo aniline                  -  0.01 mol 
3) Ethanol                                -  20 ml 
4) Glacial Acetic acid              - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of 5- Nitro isatin (0.01 mol) and p-Bromo aniline 
(0.01 mol) were added into 20 ml of absolute ethanol containing a few drops of 
glacial acetic acid in a 250-ml round bottom flask. The reaction mixture was refluxed 
for half an hour and then checked for completion by TLC. The solvent was stripped 
off and the product was recrystallized from ethanol. 
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SYNTHESIS OF 3-[(4-BROMOPHENYL) IMINO]-5-NITRO-1,3-DIHYDRO-2H  
INDOL-2-ONE: 
 
 
N
H
O
O
N
+
O
-
O +
NH2
Br
5-nitro-1H-indole-2,3-dione
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
+
O
-
O
N
Br
Step -I:
(PH 4.5)
4-bromoaniline
3-[(4-bromophenyl)imino]-5-nitro-1,3-dihydro-2H-indol-2-one  
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       SYNTHESIS OF MANNICH BASE 52 
 
       Step: 2 
 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4'-
bromo   phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline 
carboxylic acid. 
 
CHEMICALS REQUIRED 
1) 3-[(4-bromophenyl)imino]-5-nitro-1,3-dihydro-2H-indol-2-one              - 0.0025 
mol 
2) Ciprofloxacin                                                                                             - 0.0025 
mol 
3) Glacial Acetic acid                                                                                     - 20 ml 
4) 37% Formalin                                                                                             -  1 ml 
 
 
 
              PROCEDURE 
 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
(20 ml), was added 3-[(4-bromophenyl)imino]-5-nitro-1,3-dihydro-2H-indol-2-one 
(0.0025 mol) and 37% formalin(1 ml). The reaction mixture was refluxed over a 
water bath for 1–3 h. The reaction mixture was concentrated to approximately half of 
the initial volume, and the resulting precipitate was recrystallized from a mixture of 
DMF and water. 
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             SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO-    
            7[[N4-[5'NITRO-3'-[(4'-BROMO   PHENYL)-IMINO-1'-ISATINYL] METHYL]  
            N1-PIPERAZINYL]-3-QUINOLINE CARBOXYLIC ACID: 
N
H
O
N
+
O
-
O
N
Br
+
N
COOH
O
F
N
NH
Mannich Reactions
HCHO
(37% Formalin)
N
O
N
+
O
-
O
N
Br
N
N
N
F
O O
OH
Step -II: 
3-[(4-bromophenyl)imino]-5-nitro-1,3-dihydro-2H-indol-2-one
Ciprofloxacin
Glacial CH3COOH Reflux for 1 to 3 hrs
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4'-bromo   phenyl)-imino-1'-
isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
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IV) SYNTHESIS OF SCHIFF BASE23 
 
Step-I: 
Synthesis of 4-[(5-nitro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino] 
benzenesulfonamide 
 
 
            CHEMICALS REQUIRED 
                        
1) 5-Nitro Isatin                       -  0.01 mol  
2) Sulphanilamide                   -  0.01 mol 
3) Ethanol                                -  20 ml 
4) Glacial Acetic acid              - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of 5- Nitro isatin (0.01 mol) and Sulphanilamide 
(0.01 mol) were added into 20 ml of absolute ethanol containing a few drops of 
glacial acetic acid in a 250-ml round bottom flask. The reaction mixture was refluxed 
for half an hour and then checked for completion by TLC. The solvent was stripped 
off and the product was recrystallized from ethanol. 
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              SYNTHESIS OF 4-[(5-NITRO-2-OXO-1,2DIHYDRO-3H-INDOL-3-YLIDINE) 
              AMINO]BENZENESULPHONAMIDE: 
 
 
              
N
H
O
O
N
+
O
-
O +
NH2
SO2NH2
5-nitro-1H-indole-2,3-dione
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
+
O
-
O
N
SO2NH2
4-aminobenzenesulfonamide
4-[(5-nitro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzenesulfonamide
(PH 4.5)
Step -I:
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       SYNTHESIS OF MANNICH BASE 52 
 
      Step: 2 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4'   
sulphamido phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline 
carboxylic acid. 
 
CHEMICALS REQUIRED 
1) 4-[(5-nitro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino]                - 0.0025 
mol 
Benzenesulfonamide                                                                              
2) Ciprofloxacin                                                                                        - 0.0025 mol 
3) Glacial Acetic acid                                                                                - 20 ml 
4) 37% Formalin                                                                                        -  1 ml 
 
 
 
              PROCEDURE 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
 (20 ml), was added   4-[(5-nitro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino] 
Benzenesulfonamide (0.0025 mol) and 37% formalin (1 ml). The reaction mixture 
was refluxed over a water bath for 1–3 h. The reaction mixture was concentrated to 
approximately half of the initial volume, and the resulting precipitate was 
recrystallized from a mixture of DMF and water. 
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SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO-
7[[N4-[5'NITRO-3'-[(4' SULPHAMIDO PHENYL)-IMINO-1'-ISATINYL] 
METHYL] N1-PIPERAZINYL]-3-QUINOLINE CARBOXYLIC ACID: 
               
N
H
O
N
SO2NH2
N
+
O
-
O + N
COOH
O
F
N
NH
Mannich ReactionsHCHO
(37% Formalin)
N
O
N
SO2NH2
N
N
N
F
O O
OH
N
+
O
-
O
Step -II:
Reflux for 1 to 3 hrs
Glacial CH3COOH
Ciprofloxacin4-[(5-nitro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzenesulfonamide
 
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4' sulphamido 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
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V) SYNTHESIS OF SCHIFF BASE.23 
 
Step-I: 
 
            Synthesis of 5-chloro-3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one 
 
 
            CHEMICALS REQUIRED 
                        
1) 5-Chloro Isatin           -  0.01 mol  
2) p-Nitro aniline          -  0.01 mol 
3) Ethanol                       -  20 ml 
4) Glacial Acetic acid     - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of 5- Chloro isatin (0.01 mol) and p-Nitro aniline 
(0.01 mol) were added into 20 ml of absolute ethanol containing a few drops of 
glacial acetic acid in a 250-ml round bottom flask. The reaction mixture was refluxed 
for half an hour and then checked for completion by TLC. The solvent was stripped 
off and the product was recrystallized from ethanol. 
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        SYNTHESIS OF 5-CHLORO-3-[(4-NITROPHENYL)IMINO]-1,3-DIHYDRO 
        -2H- INDOL-2-ONE: 
 
 
        
N
H
O
O
Cl
+
NH2
NO2
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
NO2
Cl
4-nitroaniline
Step -I:
(PH 4.5)
5-chloro-1H-indole-2,3-dione
5-chloro-3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one  
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       SYNTHESIS OF MANNICH BASE 52  
 
       Step: 2 
 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro -3'-[(4'- 
nitro phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic 
acid. 
 
CHEMICALS REQUIRED 
1) 5-chloro-3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one  - 0.0025 mol 
2) Ciprofloxacin                                                                                 - 0.0025 mol 
3) Glacial Acetic acid                                                                         - 20 ml 
4) 37% Formalin                                                                                -  1 ml 
 
 
 
              PROCEDURE 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
(20 ml), was added 5-chloro-3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one 
(0.0025 mol) and 37% formalin(1 ml). The reaction mixture was refluxed over a 
water bath for 1–3 h. The reaction mixture was concentrated to approximately half of 
the initial volume, and the resulting precipitate was recrystallized from a mixture of 
DMF and water. 
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SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO-7[[N4-
[5'CHLORO -3'-[(4'- NITRO PHENYL)-IMINO-1'-ISATINYL] METHYL] N1-
PIPERAZINYL]-3-QUINOLINE CARBOXYLIC ACID: 
  
N
H
O
N
NO2
Cl
+
N
COOH
O
F
N
NH
Mannich Reactions
HCHO
(37% Formalin)
N
O
N
NO2
N
N
N
F
O O
OH
Cl
Step -II:
5-chloro-3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one Ciprofloxacin
Glacial CH3COOH
Reflux for 1 to 3 hrs
 
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro -3'-[(4'- nitro phenyl)-
imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
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VI)  SYNTHESIS OF SCHIFF BASE23 
 
Step-I: 
 
Synthesis of 4-[(5-chloro-2-oxo-1, 2-dihydro-3H-indol-3 ylidene)amino] 
benzoic acid 
 
 
            CHEMICALS REQUIRED 
                        
1) 5-Chloro Isatin                    -  0.01 mol  
2) Para Amino Benzoic Acid  -  0.01 mol 
3) Ethanol                                -  20 ml 
4) Glacial Acetic acid              - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of 5- Chloro isatin (0.01 mol) and Para Amino 
Benzoic Acid (0.01 mol) were added into 20 ml of absolute ethanol containing a few 
drops of glacial acetic acid in a 250-ml round bottom flask. The reaction mixture was 
refluxed for half an hour and then checked for completion by TLC. The solvent was 
stripped off and the product was recrystallized from ethanol. 
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               SYNTHESIS OF 4-[(5-CHLORO-2-OXO-1, 2-DIHYDRO-3H-INDOL-3   
               YLIDENE)AMINO] BENZOIC ACID: 
 
 
 
                
N
H
O
O
Cl
+
NH2
COOH
4-aminobenzoic acid
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
COOH
Cl
5-chloro-1H-indole-2,3-dione
4-[(5-chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzoic acid
(PH 4.5)
Step -I:
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       SYNTHESIS OF MANNICH BASE 52 
 
       Step: 2 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro-3'-[(4'-
carboxy phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic 
acid. 
 
CHEMICALS REQUIRED 
1) 4-[(5-chloro-2-oxo-1, 2-dihydro-3H-indol-3 ylidene) amino] 
benzoic acid                                                                                         - 0.0025mol 
                   
2) Ciprofloxacin                                                                                       - 0.0025 mol 
3) Glacial Acetic acid                                                                               - 20 ml 
4) 37% Formalin                                                                                       -  1 ml 
 
 
 
              PROCEDURE 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
(20 ml), was added 4-[(5-chloro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino] 
benzoic acid (0.0025 mol) and 37% formalin (1 ml). The reaction mixture was 
refluxed over a water bath for 1–3 h. The reaction mixture was concentrated to 
approximately half of the initial volume, and the resulting precipitate was 
recrystallized from a mixture of DMF and water. 
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SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO-7[[N4-
[5'CHLORO-3'-[(4'-CARBOXY PHENYL)-IMINO-1'-ISATINYL] METHYL] N1-
PIPERAZINYL]-3-QUINOLINE CARBOXYLIC ACID: 
 
N
H
O
N
COOH
Cl
+
N
COOH
O
F
N
NH
Mannich Reactions
HCHO
(37% Formalin)
N
O
N
COOH
N
N
N
F
O O
OH
Cl
Step -II:
4-[(5-chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzoic acid
Glacial CH3COOH
Reflux for 1 to 3 hrs
Ciprofloxacin
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'-chloro-3'-[(4'-carboxy phenyl)-
imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
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VII) SYNTHESIS OF SCHIFF BASE23 
Step-I: 
 
                        Synthesis of 3-[(4-bromophenyl)imino]-5-chloro-1,3-dihydro-2H-indol- 
                        2-one 
 
 
            CHEMICALS REQUIRED 
                        
1) 5-Chloro Isatin                    -  0.01 mol  
2) p-Bromo aniline                  -  0.01 mol 
3) Ethanol                                -  20 ml 
4) Glacial Acetic acid              - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of 5- Chloro isatin (0.01 mol) and p-Bromo aniline 
(0.01 mol) were added into 20 ml of absolute ethanol containing a few drops of 
glacial acetic acid in a 250-ml round bottom flask. The reaction mixture was refluxed 
for half an hour and then checked for completion by TLC. The solvent was stripped 
off and the product was recrystallized from ethanol. 
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   SYNTHESIS OF 3-[(4-BROMOPHENYL)IMINO]-5-CHLORO-1,3-DIHYDRO-2H-  
   INDOL-2-ONE: 
 
 
 
 
N
H
O
O
Cl +
NH2
Br
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
Br
Cl
Step -I:
(PH 4.5)
4-bromoaniline5-chloro-1H-indole-2,3-dione
3-[(4-bromophenyl)imino]-5-chloro-1,3-dihydro-2H-indol-2-one  
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       SYNTHESIS OF MANNICH BASE 52 
       Step: 2 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro-3'-[(4'-
bromo   phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline 
carboxylic acid. 
 
CHEMICALS REQUIRED 
1) 3-[(4-bromophenyl)imino]-5-chloro-1,3-dihydro-2H-indol-2-one           - 0.0025 
mol 
2) Ciprofloxacin                                                                                             - 0.0025 
mol 
3) Glacial Acetic acid                                                                                     - 20 ml 
4) 37% Formalin                                                                                             -  1 ml 
 
 
 
              PROCEDURE 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
(20 ml), was added 3-[(4-bromophenyl)imino]-5-chloro-1,3-dihydro-2H-indol-2-one 
(0.0025 mol) and 37% formalin(1 ml). The reaction mixture was refluxed over a 
water bath for 1–3 h. The reaction mixture was concentrated to approximately half of 
the initial volume, and the resulting precipitate was recrystallized from a mixture of 
DMF and water. 
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 SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO-7[[N4-
[5'CHLORO-3'-[(4'-BROMO   PHENYL)-IMINO-1'-ISATINYL] METHYL] N1-
PIPERAZINYL]-3-QUINOLINE CARBOXYLIC ACID. 
 
N
H
O
N
Br
Cl +
N
COOH
O
F
N
NH
Mannich Reactions
HCHO
(37% Formalin)
N
O
N
Br
N
N
N
F
O O
OH
Cl
Step -II:
3-[(4-bromophenyl)imino]-5-chloro-1,3-dihydro-2H-indol-2-one Ciprofloxacin
Glacial CH3COOH
Reflux for 1 to 3 hrs
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro-3'-[(4'-bromo   phenyl)-
imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
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VIII) SYNTHESIS OF SCHIFF BASE23 
 
Step-I: 
 
Synthesis of 4-[(5-chloro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino]    
benzenesulfonamide 
 
 
            CHEMICALS REQUIRED 
                        
1) 5-Chloro Isatin                    -  0.01 mol  
2) Sulphanilamide                   -  0.01 mol 
3) Ethanol                                -  20 ml 
4) Glacial Acetic acid              - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of 5- Chloro isatin (0.01 mol) and Sulphanilamide 
(0.01 mol) were added into 20 ml of absolute ethanol containing a few drops of 
glacial acetic acid in a 250-ml round bottom flask. The reaction mixture was refluxed 
for half an hour and then checked for completion by TLC. The solvent was stripped 
off and the product was recrystallized from ethanol. 
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      SYNTHESIS OF 4-[(5-CHLORO-2-OXO-1, 2-DIHYDRO-3H-INDOL-3-YLIDENE)   
      
      AMINO]    BENZENESULFONAMIDE: 
 
 
 
 
              
N
H
O
O
Cl
+
NH2
SO2NH2
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
SO2NH2
Cl
4-aminobenzenesulfonamide
5-chloro-1H-indole-2,3-dione
4-[(5-chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzenesulfonamide
Step -I:
(PH 4.5)
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       SYNTHESIS OF MANNICH BASE 52 
       Step: 2 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro-3'-[(4'   
sulphamido phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline 
carboxylic acid. 
 
CHEMICALS REQUIRED 
1) 4-[(5-chloro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino]            
Benzenesulfonamide                                                                    - 0.0025mol                         
2) Ciprofloxacin                                                                               - 0.0025 mol 
3) Glacial Acetic acid                                                                       - 20 ml 
4) 37% Formalin                                                                               -  1 ml 
 
 
 
              PROCEDURE 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
 (20 ml), was added   4-[(5-chloro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino] 
Benzenesulfonamide (0.0025 mol) and 37% formalin (1 ml). The reaction mixture 
was refluxed over a water bath for 1–3 h. The reaction mixture was concentrated to 
approximately half of the initial volume, and the resulting precipitate was 
recrystallized from a mixture of DMF and water. 
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SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO-7[[N4-
[5'CHLORO-3'-[(4'   SULPHAMIDO PHENYL)-IMINO-1'-ISATINYL] METHYL] N1-
PIPERAZINYL]-3-QUINOLINE CARBOXYLIC ACID: 
   
N
H
O
N
SO2NH2
Cl + N
COOH
O
F
N
NH
Mannich Reactions
HCHO
(37% Formalin)
N
O
N
SO2NH2
N
N
N
F
O O
OH
Cl
Step -I:
Reflux for 1 to 3 hrs
Glacial CH3COOH
Ciprofloxacin4-[(5-chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzenesulfonamide
 
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro-3'-[(4' sulphamido 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
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IX) SYNTHESIS OF SCHIFF BASE.23 
 
Step-I: 
 
            Synthesis of 3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one 
 
 
            CHEMICALS REQUIRED 
                        
1)  Isatin                         -  0.01 mol  
2)  p-Nitro aniline          -  0.01 mol 
3) Ethanol                       -  20 ml 
4) Glacial Acetic acid     - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of Isatin (0.01 mol) and p-Nitro aniline (0.01 mol) 
were added into 20 ml of absolute ethanol containing a few drops of glacial acetic 
acid in a 250-ml round bottom flask. The reaction mixture was refluxed for half an 
hour and then checked for completion by TLC. The solvent was stripped off and the 
product was recrystallized from ethanol. 
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    SYNTHESIS OF 3-[(4-NITROPHENYL)IMINO]-1,3-DIHYDRO-2H- 
     
    INDOL-2-ONE: 
 
 
 
 
        
N
H
O
O +
NH2
NO2
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
NO2
4-nitroaniline
Step -I:
(PH 4.5)
1H-indole-2,3-dione
3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one  
 
 
 
 
72 
 
 
Chapter‐I I I                                                                                            Synthesis                             
 
 
       SYNTHESIS OF MANNICH BASE 52  
 
       Step: 2 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'_[(4'- nitro 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
 
CHEMICALS REQUIRED 
1) 3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one                 - 0.0025 mol 
2) Ciprofloxacin                                                                                 - 0.0025 mol 
3) Glacial Acetic acid                                                                         - 20 ml 
4) 37% Formalin                                                                                -  1 ml 
 
 
 
              PROCEDURE 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
(20 ml), was added 3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one (0.0025 
mol) and 37% formalin(1 ml). The reaction mixture was refluxed over a water bath 
for 1–3 h. The reaction mixture was concentrated to approximately half of the initial 
volume, and the resulting precipitate was recrystallized from a mixture of DMF and 
water. 
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SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO-7[[N4-
[3'_[(4'- NITRO PHENYL)-IMINO-1'-ISATINYL] METHYL] N1-PIPERAZINYL]-3-
QUINOLINE CARBOXYLIC ACID: 
 
  
N
H
O
N
NO2
+
N
COOH
O
F
N
NH
Mannich ReactionsHCHO
(37% Formalin)
N
O
N
NO2
N
N
N
F
O O
OH
Step -II:
Ciprofloxacin
Glacial CH3COOH
Reflux for 1 to 3 hrs
3-[(4-nitrophenyl)imino]-1,3-dihydro-2H-indol-2-one
 
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'- nitro phenyl)-imino-1'-
isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
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X)  SYNTHESIS OF SCHIFF BASE23 
 
Step-I: 
 
Synthesis of 4-[(2-oxo-1, 2-dihydro-3H-indol-3 ylidene) amino] benzoic 
acid 
  
            CHEMICALS REQUIRED 
 
                        
1) Isatin                                    -  0.01 mol  
2) Para Amino Benzoic Acid  -  0.01 mol 
3) Ethanol                                -  20 ml 
4) Glacial Acetic acid              - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of Isatin (0.01 mol) and Para Amino Benzoic Acid 
(0.01 mol) were added into 20 ml of absolute ethanol containing a few drops of 
glacial acetic acid in a 250-ml round bottom flask. The reaction mixture was refluxed 
for half an hour and then checked for completion by TLC. The solvent was stripped 
off and the product was recrystallized from ethanol. 
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         SYNTHESIS OF 4-[(2-OXO-1, 2-DIHYDRO-3H-INDOL-3 YLIDENE) AMINO]      
       
         BENZOIC ACID: 
 
 
 
 
                
N
H
O
O +
NH2
COOH
4-aminobenzoic acid
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
COOH
(PH 4.5)
Step -I:
1H-indole-2,3-dione
4-[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzoic acid  
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       SYNTHESIS OF MANNICH BASE 52 
 
       Step: 2 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-carboxy 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
 
CHEMICALS REQUIRED 
1) 4-[(2-oxo-1, 2-dihydro-3H-indol-3 ylidene) amino] 
 benzoic acid                                                                                         - 0.0025mol 
 
2) Ciprofloxacin                                                                                        - 0.0025 mol 
3) Glacial Acetic acid                                                                                - 20 ml 
4) 37% Formalin                                                                                        -  1 ml 
 
 
 
              PROCEDURE 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
(20 ml), was added 4-[(2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino] benzoic acid 
(0.0025 mol) and 37% formalin (1 ml). The reaction mixture was refluxed over a 
water bath for 1–3 h. The reaction mixture was concentrated to approximately half of 
the initial volume, and the resulting precipitate was recrystallized from a mixture of 
DMF and water. 
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SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO-7[[N4-[3'-
[(4'-CARBOXY PHENYL)-IMINO-1'-ISATINYL] METHYL] N1-PIPERAZINYL]-3-
QUINOLINE CARBOXYLIC ACID: 
 
N
H
O
N
COOH
+
N
COOH
O
F
N
NH
Mannich Reactions
HCHO
(37% Formalin)
N
O
N
COOH
N
N
N
F
O O
OH
Step -I:
Glacial CH3COOH
Reflux for 1 to 3 hrs
Ciprofloxacin
4-[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzoic acid
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-carboxy phenyl)-imino-1'-
isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
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XI) SYNTHESIS OF SCHIFF BASE23 
Step-I: 
 
                        Synthesis of 3-[(4-bromophenyl)imino]-1,3-dihydro-2H-indol-2-one 
 
 
            CHEMICALS REQUIRED 
                        
1)  Isatin                                   -  0.01 mol  
2) p-Bromo aniline                  -  0.01 mol 
3) Ethanol                                -  20 ml 
4) Glacial Acetic acid              - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of Isatin (0.01 mol) and p-Bromo aniline (0.01 mol) 
were added into 20 ml of absolute ethanol containing a few drops of glacial acetic 
acid in a 250-ml round bottom flask. The reaction mixture was refluxed for half an 
hour and then checked for completion by TLC. The solvent was stripped off and the 
product was recrystallized from ethanol. 
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SYNTHESIS OF 3-[(4-BROMOPHENYL)IMINO]-1,3-DIHYDRO-2H- 
 
INDOL-2-ONE: 
 
 
 
N
H
O
O +
NH2
Br
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
Br
Step -I:
(PH 4.5)
4-bromoaniline
1H-indole-2,3-dione
3-[(4-bromophenyl)imino]-1,3-dihydro-2H-indol-2-one  
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       SYNTHESIS OF MANNICH BASE 52 
 
       Step: 2 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-bromo   
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
 
CHEMICALS REQUIRED 
1) 3-[(4-bromophenyl)imino]-1,3-dihydro-2H-indol-2-one           - 0.0025 mol 
2) Ciprofloxacin                                                                              - 0.0025 mol 
3) Glacial Acetic acid                                                                      - 20 ml 
4) 37% Formalin                                                                              -  1 ml 
 
 
 
              PROCEDURE 
 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
(20 ml), was added 3-[(4-bromophenyl)imino]-1,3-dihydro-2H-indol-2-one (0.0025 
mol) and 37% formalin(1 ml). The reaction mixture was refluxed over a water bath 
for 1–3 h. The reaction mixture was concentrated to approximately half of the initial 
volume, and the resulting precipitate was recrystallized from a mixture of DMF and 
water. 
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SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO-7[[N4-[3'-
[(4'-BROMO   PHENYL)-IMINO-1'-ISATINYL] METHYL] N1-PIPERAZINYL]-3-
QUINOLINE CARBOXYLIC ACID: 
 
N
H
O
N
Br
+
N
COOH
O
F
N
NH
Mannich Reactions
HCHO
(37% Formalin)
N
O
N
Br
N
N
N
F
O O
OH
Step -I:
Ciprofloxacin
Glacial CH3COOH
Reflux for 1 to 3 hrs
3-[(4-bromophenyl)imino]-1,3-dihydro-2H-indol-2-one
 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-bromo   
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
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XII) SYNTHESIS OF SCHIFF BASE23 
 
Step-I: 
 
Synthesis of 4-[(2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino]    
benzenesulfonamide 
 
 
            CHEMICALS REQUIRED 
                        
1) Isatin                                   -  0.01 mol   
2) Sulphanilamide                   -  0.01 mol 
3) Ethanol                                -  20 ml 
4) Glacial Acetic acid              - 2 drops 
 
              PROCEDURE  
 
Equimolar quantities of Isatin (0.01 mol) and Sulphanilamide (0.01 mol) 
were added into 20 ml of absolute ethanol containing a few drops of glacial acetic 
acid in a 250-ml round bottom flask. The reaction mixture was refluxed for half an 
hour and then checked for completion by TLC. The solvent was stripped off and the 
product was recrystallized from ethanol. 
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           SYNTHESIS OF 4-[(2-OXO-1, 2-DIHYDRO-3H-INDOL-3-YLIDENE) AMINO]       
      
           BENZENESULFONAMIDE: 
 
 
 
              
N
H
O
O +
NH2
SO2NH2
Reflux for 1/2 hour
C2H5OH
CH3COOH
N
H
O
N
SO2NH2
4-aminobenzenesulfonamide
Step -I:
(PH 4.5)
1H-indole-2,3-dione
4-[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzenesulfonamide  
 
 
 
84 
 
 
Chapter‐I I I                                                                                            Synthesis                             
 
 
       SYNTHESIS OF MANNICH BASE 52 
       Step: 2 
Synthesis of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'sulphamido 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
 
CHEMICALS REQUIRED 
1) 4-[(2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino]            
Benzenesulfonamide                                                                   - 0.0025mol                          
2) Ciprofloxacin                                                                               - 0.0025 mol 
3) Glacial Acetic acid                                                                       - 20 ml 
4) 37% Formalin                                                                               -  1 ml 
 
 
 
              PROCEDURE 
 
To a solution of 1-cyclo propyl-6-fluoro-1, 4-dihydro-7-piperazin-1-yl-4-
oxo   quinoline-3-carboxylic acid (Ciprofloxacin 0.0025 mol) in glacial acetic acid 
 (20 ml), was added   4-[(2-oxo-1, 2-dihydro-3H-indol-3-ylidene) amino] 
Benzenesulfonamide (0.0025 mol) and 37% formalin (1 ml). The reaction mixture 
was refluxed over a water bath for 1–3 h. The reaction mixture was concentrated to 
approximately half of the initial volume, and the resulting precipitate was 
recrystallized from a mixture of DMF and water. 
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SYNTHESIS OF 1-CYCLOPROPYL-6-FLUORO-1, 4-DIHYDRO-4-OXO-7[[N4-[3'-
[(4'SULPHAMIDO PHENYL)-IMINO-1'-ISATINYL] METHYL] N1-PIPERAZINYL]-
3-QUINOLINE CARBOXYLIC ACID. 
 
N
H
O
N
SO2NH2
+ N
COOH
O
F
N
NH
Mannich Reactions
HCHO
(37% Formalin)
N
O
N
SO2NH2
N
N
N
F
O O
OH
Step -II:
Reflux for 1 to 3 hrs
Glacial CH3COOH
Ciprofloxacin4-[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]benzenesulfonamide
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4' sulphamido phenyl)-
imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 PHYSICAL DATA OF TITLED COMPOUNDS 
                                                                                                     Table No :1 
 
Compound 
    Code 
Chemical Name Molecular 
Formula 
 Molecular 
Weight 
(grams) 
Percentage 
Yield 
AS 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4'- 
nitro phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-
quinoline carboxylic acid. 
 
C32H26FN7O8 655.589 94.05% 
A1S 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[ 5'nitro-3'-[(4'-
carboxy phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-
quinoline carboxylic acid. 
 
C33H27FN6O8 654.601 92.86% 
A2S 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4'-
bromo phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-
quinoline carboxylic acid. 
 
C32H26BrFN6O6 689.488 92.08% 
A3S 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4' 
sulphamido phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-
quinoline carboxylic acid. 
 
C32H28FN7O8S 689.670 94.87% 
BS 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5' chloro -3'-
[(4'- nitro phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-
quinoline carboxylic acid.  
C32H26ClFN6O6 645.037 94.14% 
B1S 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[ 5'chloro-3'-
[(4'-carboxy phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-
3-quinoline carboxylic acid. 
 
C33H27ClFN5O6 644.049 95.27% 
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Compound 
    Code 
Chemical Name Molecular 
Formula 
Molecular 
Weight 
(grams) 
Percentage 
Yield 
B2S 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro-3'-
[(4'-bromo phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-
quinoline carboxylic acid. 
 
C32H26BrClFN5O4 678.935 92.99% 
B3S 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro-3'-[(4' 
sulphamido phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-
quinoline carboxylic acid. 
 
C32H28ClFN6O6S 679.118 95.88% 
CS 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-nitro 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline 
carboxylic acid. 
 
C32H27FN6O6 610.592 98.36% 
C1S 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-carboxy 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline 
carboxylic acid. 
C33H28FN5O6 609.604 97.83% 
C2S 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-bromo 
phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline 
carboxylic acid. 
 
C32H27BrFN5O4 644.490 94.38% 
C3S 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[3'-[(4'-
Sulphamido phenyl)-imino-1'-isatinyl] methyl] N1-piperazinyl]-3-
quinoline carboxylic acid  
C32H29FN6O6S 644.673 95.09% 
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MELTING POINT ANALYSIS 
            Melting point was found in an open end capillary tube method by electrically 
heating melting point apparatus. 
                The melting point of synthesized compounds is given in the table no:2 
Table No :2 
 
S.NO 
 
COMPOUND 
 
MELTING POINT 0C 
    1.  AS 126-129 
2. A1S 124-128 
3. A2S 142-145 
4. A3S 134-138 
5. BS 115-118 
6. B1S 136-138 
7. B2S 151-155 
8. B3S 141-143 
9. CS 124-126 
10. C1S 131-134 
11. C2S 147-151 
12. C3S 159-162 
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THIN LAYER CHROMATOGRAPHY ANALYSIS 
           Thin layer chromatography analysis was carried out by using Silica gel G (0.5mm 
thickness) coated over glass plate (12x20cm) as stationary phase, Chloroform: Methanol (9:1) 
as mobile phase, the spots were visualized by iodine vapours. 
              The Rf value of the synthesized compounds are given in the table no:3 
Table No: 3 
S.No COMPOUND Rf  VALUE 
1. AS 0.7846 
2. A1S 0.7941 
3. A2S 0.7969 
4. A3S 0.7681 
5. BS 0.8833 
6. B1S 0.8095 
7. B2S 0.7857 
8. B3S 0.8000 
9. CS 0.8750 
10. C1S 0.9077 
11. C2S 0.8281 
12. C3S 0.8593 
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                          INFRA RED SPECTRAL ANALYSIS 65-71 
 
   The structure of the synthesized compounds was elucidated by PERKIN-ELMER FT-IR 
spectrophotometry using potassium bromide disc. The infra red values were measured as 
wave number in cm-1 and the results are shown below.  
 
                                                                    AS 
 
                               
N
O
N
+
O
-
O
N
NO2
N
N
N
F
O O
OH
 
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[ 5'nitro-3'-[(4'-nitro phenyl)-imino-1'-
isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1695.65 cm-1 
3. C=N Stretching Vibration                 - 1635.10 cm-1 
4. C=C Aryl Stretching Vibration         - 1590.26 cm-1 
5. =NH imino Stretching Vibration       - 3320.85 cm-1 
6. Aromatic nitro group                         - 1550.26 & 1350.73 cm-1 
7. Para substitution in benzene ring       - 832.39 cm-1 
8. Methylene bridge                               - 2934.33 cm-1 
9. Cyclo propane Stretching Vibration  - 3050.30 cm-1 
10. C-F Stretching Vibration                   - 1030.07 cm-1 
11. Carboxylic acid Stretching Vibration- 2596.59 cm-1 
12. OH bending vibration for COOH      - 945.03 cm-1                                        
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                                                                  A1S 
 
                               
N
O
N
+
O
-
O
N
COOH
N
N
N
F
O O
OH
 
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[ 5'nitro-3'-[(4'-carboxy phenyl)-imino-1'-
isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1677.51 cm-1 
3. C=N Stretching Vibration                 - 1595.69 cm-1 
4. =NH imino Stretching Vibration       - 3352.86 cm-1 
5. Aromatic nitro group                         - 1330.57 cm-1 
6. Para substitution in benzene ring       - 832.24 cm-1 
7. Methylene bridge                               - 2925.47 cm-1 
8. Cyclo propane Stretching Vibration  - 3082.33 cm-1 
9. C-F Stretching Vibration                   - 1048.12 cm-1 
10. Carboxylic acid Stretching Vibration- 2856.66 cm-1 
11. OH bending vibration for COOH      - 964.50 cm-1                                        
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A2S 
 
N
O
N
+
O
-
O
N
Br
N
N
N
F
O O
OH
 
 
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[ 5'nitro-3'-[(4'-bromophenyl)-imino-1'-
isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1745.26 cm-1 
3. C=N Stretching Vibration                 - 1641.22 cm-1 
4. C=C Aryl Stretching Vibration         - 1615.05 cm-1 
5. =NH imino Stretching Vibration       - 3412.25 cm-1 
6. Aromatic nitro group                         - 1350.56 cm-1 
7. Para substitution in benzene ring       - 835.26 cm-1 
8. Methylene bridge                               - 2924.54 cm-1 
9. Cyclo propane Stretching Vibration  - 3053.98 cm-1 
10. C-F Stretching Vibration                   - 1035.96 cm-1 
11. Carboxylic acid Stretching Vibration- 2501.53 cm-1 
12. OH bending vibration for COOH      - 954.87 cm-1   
13. C-Br Stretching Vibration                  - 592.45 cm-1 
 
93 
 
       Chapter‐V                                                                                     Infra Red Spectroscopic Analysis  
 
                                                                A3S 
 
                               
N
O
N
SO2NH2
N
N
N
F
O O
OH
N
+
O
-
O
 
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'nitro-3'-[(4'-Sulphamido phenyl)-imino-
1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1721.16 cm-1 
3. C=N Stretching Vibration                 - 1638.77 cm-1 
4. C=C Aryl stretching Vibration          - 1603.55 cm-1 
5. NH Asymmetric Stretching Vibration - 3356.89 cm-1 
6. Para substitution in benzene ring       - 858.43 cm-1 
7. Methylene bridge                               - 2930.33 cm-1 
8. Cyclo propane Stretching Vibration  - 3053.98 cm-1 
9. C-F Stretching Vibration                   - 1096.18 cm-1 
10. Carboxylic acid Stretching Vibration- 2515.87 cm-1 
11. S-N Stretching Vibration                   -  901.33 cm-1  
12. SO2  Asymmetric Stretching Vibration- 1332.66 cm-1 
13. SO2  Symmetric Stretching Vibration  - 1155.23 cm-1 
14. Aromatic NO2 group                            - 1540.15 cm-1 
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                                                                    BS 
 
                               
N
O
N
NO2
N
N
N
F
O O
OH
Cl
 
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[ 5'chloro-3'-[(4'-nitro phenyl)-imino-1'-
isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1742.37 cm-1 
3. C=N Stretching Vibration                 - 1678.84 cm-1 
4. C=C Aryl Stretching Vibration         - 1597.22 cm-1 
5. =NH imino Stretching Vibration       - 3364.94 cm-1 
6. Aromatic nitro group                         - 1354.26 cm-1 
7. Para substitution in benzene ring       - 830.65 cm-1 
8. Methylene bridge                               - 2924.73 cm-1 
9. Cyclo propane Stretching Vibration  - 3062.09 cm-1 
10. C-Cl Stretching Vibration                   -751.73 cm-1, 695.19 cm-1 
11. Carboxylic acid Stretching Vibration- 2839.89 cm-1 
12. OH bending vibration for COOH      - 963.11 cm-1    
13. C-F Stretching Vibration                    - 1111.98 cm-1 
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                                                                B1S 
 
                               
N
O
N
COOH
N
N
N
F
O O
OH
Cl
 
 
1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5'chloro-3'[(4'-carboxy phenyl)-imino-1'-
isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1760.11 cm-1 
3. C=N Stretching Vibration                 - 1738.62 cm-1 
4. C=C Aryl stretching Vibration          - 1605.79 cm-1 
5. =NH imino Stretching Vibration       - 3399.98 cm-1 
6. Para substitution in benzene ring       - 832.79 cm-1 
7. Methylene bridge                               - 2922.45 cm-1 
8. Cyclo propane Stretching Vibration  - 3064.91 cm-1 
9. C-F Stretching Vibration                   - 1001.11 cm-1 
10. Carboxylic acid Stretching Vibration- 2516.98 cm-1 
11. OH bending vibration for COOH      - 955.43 cm-1                                        
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                                                                    B2S 
 
                               
N
O
N
Br
N
N
N
F
O O
OH
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1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[ 5'chloro-3'-[(4'-bromo phenyl)-imino-1'-
isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1720.64 cm-1 
3. C=N Stretching Vibration                 - 1621.09 cm-1 
4. C=C Aryl Stretching Vibration         - 1580.80 cm-1 
5. =NH imino Stretching Vibration       - 3398.76 cm-1 
6. C-Br Stretching Vibration                   -549.62 cm-1 
7. Para substitution in benzene ring       - 823.46 cm-1 
8. Methylene bridge                               - 2927.19 cm-1 
9. Cyclo propane Stretching Vibration  - 3127.49 cm-1 
10. C-Cl Stretching Vibration                   -746.18 cm-1, 668.18 cm-1 
11. Carboxylic acid Stretching Vibration- 2837.99 cm-1 
12. OH bending vibration for COOH      - 951.31 cm-1      
13. C-F Stretching Vibration                    - 1084.86 cm-1                                
 
97 
 
Chapter‐V                                                                                       Infra Red Spectroscopic Analysis  
 
B3S 
 
                               
N
O
N
SO2NH2
N
N
N
F
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1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5' chloro-3'-[(4'-Sulphamido phenyl)-
imino-1'-isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1748.23 cm-1 
3. C=N Stretching Vibration                 - 1680.34 cm-1 
4. C=C Aryl stretching Vibration          - 1615.09 cm-1 
5. NH Asymmetric Stretching Vibration - 3387.45 cm-1 
6. Para substitution in benzene ring       - 835.26 cm-1 
7. Methylene bridge                               - 2924.31 cm-1 
8. Cyclo propane Stretching Vibration  - 3039.71 cm-1 
9. C-F Stretching Vibration                   - 1091.96 cm-1 
10. Carboxylic acid Stretching Vibration- 2749.12 cm-1 
11. S-N Stretching Vibration                   -  900.11cm-1  
12. SO2  Asymmetric Stretching Vibration- 1330.45 cm-1 
13. SO2  Symmetric Stretching Vibration  - 1151.29 cm-1 
14. C-Cl Stretching Vibration                    - 736.45 cm-1 
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                                                                    CS 
 
                               
N
O
N
NO2
N
N
N
F
O O
OH
 
 
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[3'-[(4'-nitro phenyl)-imino-1'-isatinyl] 
methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1737.25 cm-1 
3. C=N Stretching Vibration                 - 1678.98 cm-1 
4. C=C Aryl Stretching Vibration         - 1596.90 cm-1 
5. =NH imino Stretching Vibration       - 3370.28 cm-1 
6. Aromatic nitro group                         - 1351.35 cm-1 
7. Para substitution in benzene ring       - 831.70 cm-1 
8. Methylene bridge                               - 2925.61 cm-1 
9. Cyclo propane Stretching Vibration  - 3103.80 cm-1 
10. Carboxylic acid Stretching Vibration- 2855.52 cm-1 
11. OH bending vibration for COOH      - 945.39 cm-1    
12. C-F Stretching Vibration                    - 1110.28 cm-1 
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                                                                C1S 
 
                               
N
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N
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1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[3'-[(4'-carboxy phenyl)-imino-1'-isatinyl] 
methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1736.64 cm-1 
3. C=N Stretching Vibration                 - 1678.82 cm-1 
4. C=C Aryl stretching Vibration          - 1607.98 cm-1 
5. =NH imino Stretching Vibration       - 3423.89 cm-1 
6. Para substitution in benzene ring       - 833.94 cm-1 
7. Methylene bridge                               - 2927.71 cm-1 
8. Cyclo propane Stretching Vibration  - 3090.86 cm-1 
9. C-F Stretching Vibration                   - 1065.20 cm-1 
10. Carboxylic acid Stretching Vibration- 2843.56 cm-1 
11. OH bending vibration for COOH      - 966.32 cm-1                                        
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                                                                C2S 
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O
N
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N
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1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[3'-[(4'-bromo phenyl)-imino-1'-isatinyl] 
methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1711.48 cm-1 
3. C=N Stretching Vibration                 - 1690.12 cm-1 
4. C=C Aryl stretching Vibration          - 1614.65 cm-1 
5. =NH imino Stretching Vibration       - 3385.92 cm-1 
6. Para substitution in benzene ring       - 847.21 cm-1 
7. Methylene bridge                               - 2924.23 cm-1 
8. Cyclo propane Stretching Vibration  - 3052.91 cm-1 
9. C-F Stretching Vibration                   - 1108.34 cm-1 
10. Carboxylic acid Stretching Vibration- 2698.74 cm-1 
11. OH bending vibration for COOH      - 955.31 cm-1                                        
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                                                                C3S 
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1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[3'-[(4'-Sulphamido phenyl)-imino-1'-
isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
IR Values: 
 
1. Aromatic Compounds                       - Above 3300 cm-1 
2. C=O Stretching Vibration                 - 1739.04 cm-1 
3. C=N Stretching Vibration                 - 1666.74 cm-1 
4. C=C Aryl stretching Vibration          - 1611.46 cm-1 
5. NH Asymmetric Stretching Vibration - 3383.34 cm-1 
6. Para substitution in benzene ring       - 830.83 cm-1 
7. Methylene bridge                               - 2925.80 cm-1 
8. Cyclo propane Stretching Vibration  - 3100.31 cm-1 
9. C-F Stretching Vibration                   - 1095.05 cm-1 
10. Carboxylic acid Stretching Vibration- 2831.12 cm-1 
11. S-N Stretching Vibration                   -  900.97 cm-1  
12. SO2  Asymmetric Stretching Vibration- 1334.25 cm-1 
13. SO2  Symmetric Stretching Vibration  - 1153.37 cm-1 
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NUCLEAR MAGNETIC RESONANCE SPECTRAL ANALYSIS 66, 69, 70 
 
          The structures of the synthesized compounds were elucidated by BRUCKER 300 MHz     
FT- NMR using TMS (Tetramethyl Silane) as internal standard. The Proton Magnetic 
Resonance Spectroscopic values are measured in ߜ ppm in CDCl3. 
                                                         Sample A1S 
                                        
N
O
N
+
O
-
O
N
COOH
N
N
N
F
O O
OH
 
  1 -cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[ 5'nitro-3'-[(4'-carboxy phenyl)-imino-1'-   
  isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
                1.3              -              t,    2H,    Cyclopropane 
                                           1.6              -              s,     2H,    CH2    
      3.123           -              m,    8H,   in Piperazine 
          7.972           -              m,    4H,   Indole 
                 7.218-7.645 -   m,    6H,   Aromatic protons 
                                           11.4             -   s,     H,    COOH    
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                                                         Sample A2S 
 
                                        
N
O
N
Br
N
N
N
F
O O
OH
N
+
O
-
O
 
  1 -cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7[[N4-[ 5'nitro-3'-[(4'-bromo phenyl)-imino-1'-   
  isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid. 
 
                1.4              -              t,    2H,    Cyclopropane 
                                           1.6              -              s,     2H,    CH2    
      3.011-3.148-              m,    8H,   in Piperazine 
          8.178           -              m,    4H,   Indole 
                 7.282-7.735 -   m,    6H,   Aromatic protons 
                                           11.5             -   s,     H,    COOH    
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                                                           Sample BS 
 
                                        
N
O
N
NO2
N
N
N
F
O O
OH
Cl
 
  1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5' chloro -3'-[(4'- nitro phenyl)-imino-1'- 
   isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid.      
 
     
        1.3              -              t,    2H,    Cyclopropane 
                                           1.6              -              s,     2H,    CH2    
      3.035-3.171-              m,    8H,   in Piperazine 
          8.001           -              m,    4H,   Indole 
                 7.047-7.784 -   m,    6H,   Aromatic protons 
                                           11.4             -   s,     H,    COOH    
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Sample B2S 
 
                                        
N
O
Cl N
Br
N
N
N
F
O O
OH
 
  1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[5' chloro -3'-[(4'-bromo phenyl)-imino-1'- 
   isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid.      
 
     
        1.3              -              t,    2H,    Cyclopropane 
                                           1.6              -              s,     2H,    CH2    
      3.009-3.101-              m,    8H,   in Piperazine 
          7.964           -              m,    4H,   Indole 
                 7.028-7.761 -   m,    6H,   Aromatic protons 
                                           11.5             -   s,     H,    COOH    
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                                                         Sample C2S 
                                        
N
O
N
Br
N
N
N
F
O O
OH
 
  1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-bromo phenyl)-imino-1'-isatinyl]  
  methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
 
     
        1.3              -              t,    2H,    Cyclopropane 
                                           1.6              -              s,     2H,    CH2    
      3.010-3.102-              m,    8H,   in Piperazine 
          7.857           -              m,    4H,   Indole 
                 7.037-7.646 -   m,    6H,   Aromatic protons 
                                           11.4             -   s,     H,    COOH    
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                                                         Sample C3S 
 
                                        
N
O
N
SO2NH2
N
N
N
F
O O
OH
 
  1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7[[N4-[3'-[(4'-sulphamido phenyl)-imino-1'- 
   isatinyl] methyl] N1-piperazinyl]-3-quinoline carboxylic acid 
     
        1.3              -              t,    2H,    Cyclopropane 
                                           1.6              -              s,     2H,    CH2    
          7.857           -              m,    4H,   Indole 
                 7.037-7.646 -   m,    6H,   Aromatic protons 
                                           10.9             -   s,     H,    COOH     
                                            9.8              -              s,    2H, SO2NH2    
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ANTI-MICROBIAL SCREENING 24, 53, 73, 74 
 
Anti-bacterial and Anti-fungal activity [Cup and Plate method] 
 
PROCEDURE:  
Preparation of Muller – Hinton Agar 
Beef extract   - 300 gm 
Peptone   - 17.5 gm 
Starch    - 1.5 gm 
Agar    - 17 gm 
Cold distilled water           -          up to 1000 ml. 
 
Method: 
All the ingredients were weighed and suspended in 1000 ml of cold distilled 
water and heated to boiling.  The pH of the media was adjusted to 7.4 with 5 M 
sodium hydroxide solution.  Then 5 – 20 ml of this agar medium was transferred into 
each boiling tube and plugged with non- absorbent cotton.   
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 The tube containing agar medium was sterilized by pressure controlled heat 
sterilizations technique using an autoclave at 15 lbs at 121oC for 20 minutes. 
 
             After sterilization the agar medium was melted, cooled and inoculated with G 
(+ ve) organisms like Staphylococcus aureus, Streptococcus pyogenes, G (- ve) 
organism      E .coli, Klebsilla aerogenes, and Candida albicans (Fungi) then poured 
into sterile Petri dish to get a uniform thickness of 5 – 6 mm. Cups were made out in 
the other plate using sterile cork borer (6 dm). 
 
             Then the cups were charged with appropriate concentration of the standard 
like Ciprofloxacin (30µg/ml) and Ketoconazole (50µg/ml). Likewise the cups were 
also charged with the series of newly synthesized Isatin derivatives (30µg/ml) and 
incubated at 37oC for 24 hours. The diameter of zone of inhibition around the cups 
were measured and tabulated in the following table 
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ANTI -BACTERIAL ACTIVITY OF TITLED COMPOUNDS  
AGAINST G (+ ve) ORGANISMS 
Table No: 4 
 
S. No. Compound Code 
Zone of Inhibition (mm) 
Staphylococci 
G(+ve) 
Streptococci 
G(+ve) 
1. AS 18mm 17mm 
2. A1S 19mm 18mm 
3. A2S 16mm 14mm 
4. A3S 22mm 20mm 
5. BS 21mm 19mm 
6. B1S 22mm 20mm 
7. B2S 19mm 16mm 
8. B3S 23mm 21mm 
9. CS 10mm 8mm 
10. C1S 20mm 16mm 
11. C2S 20mm 21mm 
12. C3S 20mm 19mm 
13. Solvent Control 0mm 0mm 
14. Std Ciprofloxacin 16mm 18mm 
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ANTI -BACTERIAL ACTIVITY OF TITLED COMPOUNDS  
AGAINST G (- ve) ORGANISMS 
Table No:5 
 
S. No. Compound Code 
Zone of Inhibition (mm) 
E.coli 
G(-ve) 
Klebsilla 
G(-ve) 
1. AS 23mm 16mm 
2. A1S 23mm 17mm 
3. A2S 21mm 12mm 
4. A3S 24mm 18mm 
5. BS 28mm 10mm 
6. B1S 27mm 20mm 
7. B2S 28mm 14mm 
8. B3S 30mm 15mm 
9. CS 20mm 10mm 
10. C1S 25mm 12mm 
11. C2S 26mm 16mm 
12. C3S 30mm 13mm 
13. Solvent Control 0mm 0mm 
14. Std Ciprofloxacin 23mm 18mm 
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ANTI –FUNGAL ACTIVITY OF TITLED COMPOUNDS 
 
Table No: 6 
 
S. No. Compound Code 
Zone of Inhibition (mm) 
Candida albicans 
 
1. AS 10mm 
2. A1S 14mm 
3. A2S 12mm 
4. A3S 13mm 
5. BS 14mm 
6. B1S 12mm 
7. B2S 14mm 
8. B3S 13mm 
9. CS 10mm 
10. C1S 12mm 
11. C2S 13mm 
12. C3S 14mm 
13. Solvent Control 0mm 
14. Std Ketoconazole 18mm 
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ANALGESIC ACTIVITY 73, 75, 76 
 
 
Evaluation of analgesic activity 
 
 
 The analgesic activities of various synthesized compounds were screened by using 
acetic acid induced writhing test in mice. Mice of either sex weighing between 20 –25 gm 
were taken in14 groups of each 4 animals. 
 
 Diclofenac sodium 10mg/kg was used as a standard drug for comparison of analgesic 
activity. Writhing was induced by administration 0.2ml of 1%v/v of aceticacid through 
intraperitoneally. Record the number of abdominal contractions, trunk twist response and 
extension of hind limbs as well as the number of animals showing such response during a 
period of 25 min. 
 
 Administer all synthesized compound through I.P. Half an hour later administer 
aceticacid solution at 1ml/100gm B.W. Note and calculate onset and severity of writhing 
response. Note the inhibition of pain response by synthesized drugs. 
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EFFECT OF ANALGESIC ACTIVITIES OF SYNTHESIZED COMPOUNDS AGAINST 
ACETIC ACID INDUCED WRITHING TESTS IN MICE. 
Table No: 7 
GROUP COMPD DOSE NO FO WRITHES IN 
25MIN (Mean±.SEM)
%INHIBITION
G1(Normal 
control) 
Normal 
saline 
10 ml / kg 27.82±.0.42 
 
----- 
G2 (STD) Diclofenac 
sodium 
10 mg / kg 7.50±0.58. 73.04% 
G3(Treatment 
control) 
AS 5mg/ kg 8.60±0.43 69.08%*a 
G4 A1S 
 
5 mg/ kg 8.30±0.50 70.16%*a 
G5 A2S 
 
5 mg / kg 12.65±1.20 54.52% 
G6 A3S 
 
5 mg / kg 13.22±1.60 52.48% 
G7 BS 
 
5 mg / kg 8.90±0.71 68.00%*a 
G8 B1S 
 
5 mg / kg 13.05±1.12 
 
53.09% 
G9 B2S 
 
5 mg / kg 8.58±0.70 
 
69.15%*a 
G10 B3S 
 
5 mg / kg 12.60±1.20 54.70% 
G11 CS 5 mg / kg 12.15±1.06 56.09% 
 
G12 C1S 5 mg / kg 12.12±1.33 56.55% 
G13 C2S 
 
5 mg / kg 8.45±0.66 69.62%*a 
G14 C3S 
 
5 mg / kg 8.55±0.40 69.26%*a 
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• Values are expressed as Mean ± SEM 
• Values are find out by using One way ANOVA followed by Newman Keul’s 
multiple range tests. 
            *a Values are significantly different from normal control at P<0.01. 
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ULCEROGENIC ACTIVITY OF VARIOUS SYNTHESIZED 
ISATIN DERIVATIVES 74, 75, 76 
 
 
             Acute Ulcerogenic test was carried out according to the Method of Cioli et al.74 
Wistar rats were divided into 14 Groups consisting of Six animals in each group. 
 
Treatment Protocol as Follows: 
 
 
Group I                  – Served as Normal Control (Received 0.5 ml of DMSO as Vehicle) 
 
Group II                – Served as Ulcer Control (Received Diclofenac Sodium 30mg/Kg).75 
 
Group III to XIV     – Served as Treatment Control (Received Synthetic Compounds such 
                                  as AS, A1S, A2S, A3S, BS, B1S, B2S, B3S, CS, C1S, C2S, C3S 
                                  at 5 mg/Kg respectively through I.P). 
  
           All animals were tested 24 h before administration of the test compounds. After the 
drug treatment, the rats were fed normal diet for 17 h76 then they were Sacrificed.  
 The stomach was removed and opened along the Greater Curvature, washed with 
distilled water and cleaned gently by dipping in saline. The mucosal damage examined by 
means of a Magnifying lens (10X).  
 
 For each stomach the mucosal damage was assessed according to the following 
scoring system. 
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Table No: 8 
 
Score Description 
 
0.0 Normal (no injury, bleeding and latent injury) 
 
 
0.5 Latent injury (or) Widespread bleeding   
 
 (>2 mm) 
1.0 Slight injury (2-3 dotted lines) 
 
 
2.0 Severe injury (Continuous lined injury (or)    
 
5-6  dotted injuries) 
3.0 Very severe injury (Several Continuous lined  
 
injuries) 
 
 
 
The Mean Score of each treated group minus Mean Score of control group was 
regarded as the Severity Index of Gastric Mucosal damage. 
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ULCEROGENIC EFFECTS OF SYNTHESIZED COMPOUNDS IN 
 
COMPARISON WITH DICLOFENAC SODIUM. 
 
Table No: 9 
 
 
 
 
 
 
Group Dose (mg/Kg) Ratio of ulcerated 
animals 
Ulcer Index     
(Mean ± SEM) 
I 0.5 ml DMSO 0/6 0.0 ±  0.0 
 
II 30mg/Kg  Diclofenac 
sodium 
6/6 2.1 ± 0.2 
III 5 mg/Kg AS 5/6 1.8 ± 0.3 
 
IV  5 mg/Kg A1S 3/6 0.6 ± 0.1*a
 
V  5 mg/Kg A2S 2/6 0.5 ± 0.1*a
 
VI  5 mg/Kg A3S 4/6 1.9 ± 0.4 
 
VII        5 mg/Kg BS 1/6 0.5 ±0.2 *a
 
VIII 5 mg/Kg B1S 5/6 2.0 ± 0.3 
 
IX 5 mg/Kg B2S 1/6 0.8 ± 0.2*a
 
X 5 mg/Kg B3S 1/6 0.8 ± 0.2*a
 
XI        5 mg/Kg CS 5/6 1.5 ±0.5 
 
XII 5 mg/Kg C1S 5/6 1.6 ± 0.3 
 
XIII 5 mg/Kg C2S 2/6 0.6 ± 0.1*a
 
XIV 5 mg/Kg C3S 2/6 0.6 ± 0.1*a
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Values are expressed as Mean ± SEM. Data analysed by one way ANOVA followed 
by Newman Kevi’s Multiple range test. 
 
*a – Values were significantly different from control at p < 0.01. 
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ANTI-MICROBIAL SCREENING 24, 53, 73, 74 
 
Anti-bacterial and Anti-fungal activity [Cup and Plate method] 
 
PROCEDURE:  
Preparation of Muller – Hinton Agar 
Beef extract   - 300 gm 
Peptone   - 17.5 gm 
Starch    - 1.5 gm 
Agar    - 17 gm 
Cold distilled water           -          up to 1000 ml. 
 
Method: 
All the ingredients were weighed and suspended in 1000 ml of cold distilled 
water and heated to boiling.  The pH of the media was adjusted to 7.4 with 5 M 
sodium hydroxide solution.  Then 5 – 20 ml of this agar medium was transferred into 
each boiling tube and plugged with non- absorbent cotton.   
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 The tube containing agar medium was sterilized by pressure controlled heat 
sterilizations technique using an autoclave at 15 lbs at 121oC for 20 minutes. 
 
             After sterilization the agar medium was melted, cooled and inoculated with G 
(+ ve) organisms like Staphylococcus aureus, Streptococcus pyogenes, G (- ve) 
organism      E .coli, Klebsilla aerogenes, and Candida albicans (Fungi) then poured 
into sterile Petri dish to get a uniform thickness of 5 – 6 mm. Cups were made out in 
the other plate using sterile cork borer (6 dm). 
 
             Then the cups were charged with appropriate concentration of the standard 
like Ciprofloxacin (30µg/ml) and Ketoconazole (50µg/ml). Likewise the cups were 
also charged with the series of newly synthesized Isatin derivatives (30µg/ml) and 
incubated at 37oC for 24 hours. The diameter of zone of inhibition around the cups 
were measured and tabulated in the following table 
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ANTI -BACTERIAL ACTIVITY OF TITLED COMPOUNDS  
AGAINST G (+ ve) ORGANISMS 
Table No: 4 
 
S. No. Compound Code 
Zone of Inhibition (mm) 
Staphylococci 
G(+ve) 
Streptococci 
G(+ve) 
1. AS 18mm 17mm 
2. A1S 19mm 18mm 
3. A2S 16mm 14mm 
4. A3S 22mm 20mm 
5. BS 21mm 19mm 
6. B1S 22mm 20mm 
7. B2S 19mm 16mm 
8. B3S 23mm 21mm 
9. CS 10mm 8mm 
10. C1S 20mm 16mm 
11. C2S 20mm 21mm 
12. C3S 20mm 19mm 
13. Solvent Control 0mm 0mm 
14. Std Ciprofloxacin 16mm 18mm 
 
 
 
 
111 
 
 
 
Chapter‐VI                                                                                               Pharmacology‐ Antimicrobial Activity  
 
 
ANTI -BACTERIAL ACTIVITY OF TITLED COMPOUNDS  
AGAINST G (- ve) ORGANISMS 
Table No:5 
 
S. No. Compound Code 
Zone of Inhibition (mm) 
E.coli 
G(-ve) 
Klebsilla 
G(-ve) 
1. AS 23mm 16mm 
2. A1S 23mm 17mm 
3. A2S 21mm 12mm 
4. A3S 24mm 18mm 
5. BS 28mm 10mm 
6. B1S 27mm 20mm 
7. B2S 28mm 14mm 
8. B3S 30mm 15mm 
9. CS 20mm 10mm 
10. C1S 25mm 12mm 
11. C2S 26mm 16mm 
12. C3S 30mm 13mm 
13. Solvent Control 0mm 0mm 
14. Std Ciprofloxacin 23mm 18mm 
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ANTI –FUNGAL ACTIVITY OF TITLED COMPOUNDS 
 
Table No: 6 
 
S. No. Compound Code 
Zone of Inhibition (mm) 
Candida albicans 
 
1. AS 10mm 
2. A1S 14mm 
3. A2S 12mm 
4. A3S 13mm 
5. BS 14mm 
6. B1S 12mm 
7. B2S 14mm 
8. B3S 13mm 
9. CS 10mm 
10. C1S 12mm 
11. C2S 13mm 
12. C3S 14mm 
13. Solvent Control 0mm 
14. Std Ketoconazole 18mm 
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ANALGESIC ACTIVITY 73, 75, 76 
 
 
Evaluation of analgesic activity 
 
 
 The analgesic activities of various synthesized compounds were screened by using 
acetic acid induced writhing test in mice. Mice of either sex weighing between 20 –25 gm 
were taken in14 groups of each 4 animals. 
 
 Diclofenac sodium 10mg/kg was used as a standard drug for comparison of analgesic 
activity. Writhing was induced by administration 0.2ml of 1%v/v of aceticacid through 
intraperitoneally. Record the number of abdominal contractions, trunk twist response and 
extension of hind limbs as well as the number of animals showing such response during a 
period of 25 min. 
 
 Administer all synthesized compound through I.P. Half an hour later administer 
aceticacid solution at 1ml/100gm B.W. Note and calculate onset and severity of writhing 
response. Note the inhibition of pain response by synthesized drugs. 
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EFFECT OF ANALGESIC ACTIVITIES OF SYNTHESIZED COMPOUNDS AGAINST 
ACETIC ACID INDUCED WRITHING TESTS IN MICE. 
Table No: 7 
GROUP COMPD DOSE NO FO WRITHES IN 
25MIN (Mean±.SEM)
%INHIBITION
G1(Normal 
control) 
Normal 
saline 
10 ml / kg 27.82±.0.42 
 
----- 
G2 (STD) Diclofenac 
sodium 
10 mg / kg 7.50±0.58. 73.04% 
G3(Treatment 
control) 
AS 5mg/ kg 8.60±0.43 69.08%*a 
G4 A1S 
 
5 mg/ kg 8.30±0.50 70.16%*a 
G5 A2S 
 
5 mg / kg 12.65±1.20 54.52% 
G6 A3S 
 
5 mg / kg 13.22±1.60 52.48% 
G7 BS 
 
5 mg / kg 8.90±0.71 68.00%*a 
G8 B1S 
 
5 mg / kg 13.05±1.12 
 
53.09% 
G9 B2S 
 
5 mg / kg 8.58±0.70 
 
69.15%*a 
G10 B3S 
 
5 mg / kg 12.60±1.20 54.70% 
G11 CS 5 mg / kg 12.15±1.06 56.09% 
 
G12 C1S 5 mg / kg 12.12±1.33 56.55% 
G13 C2S 
 
5 mg / kg 8.45±0.66 69.62%*a 
G14 C3S 
 
5 mg / kg 8.55±0.40 69.26%*a 
 
 
 
 
 
 
115 
 
 
Chapter‐VI                                                                                                      Pharmacology‐ Analgesic Activity 
 
 
 
• Values are expressed as Mean ± SEM 
• Values are find out by using One way ANOVA followed by Newman Keul’s 
multiple range tests. 
            *a Values are significantly different from normal control at P<0.01. 
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ULCEROGENIC ACTIVITY OF VARIOUS SYNTHESIZED 
ISATIN DERIVATIVES 74, 75, 76 
 
 
             Acute Ulcerogenic test was carried out according to the Method of Cioli et al.74 
Wistar rats were divided into 14 Groups consisting of Six animals in each group. 
 
Treatment Protocol as Follows: 
 
 
Group I                  – Served as Normal Control (Received 0.5 ml of DMSO as Vehicle) 
 
Group II                – Served as Ulcer Control (Received Diclofenac Sodium 30mg/Kg).75 
 
Group III to XIV     – Served as Treatment Control (Received Synthetic Compounds such 
                                  as AS, A1S, A2S, A3S, BS, B1S, B2S, B3S, CS, C1S, C2S, C3S 
                                  at 5 mg/Kg respectively through I.P). 
  
           All animals were tested 24 h before administration of the test compounds. After the 
drug treatment, the rats were fed normal diet for 17 h76 then they were Sacrificed.  
 The stomach was removed and opened along the Greater Curvature, washed with 
distilled water and cleaned gently by dipping in saline. The mucosal damage examined by 
means of a Magnifying lens (10X).  
 
 For each stomach the mucosal damage was assessed according to the following 
scoring system. 
 
 
 
 
 
 
117 
 
 
 
Chapter‐VI                                                                                                      Pharmacology‐ Ulcerogenic Index 
 
 
 
 
 
Table No: 8 
 
Score Description 
 
0.0 Normal (no injury, bleeding and latent injury) 
 
 
0.5 Latent injury (or) Widespread bleeding   
 
 (>2 mm) 
1.0 Slight injury (2-3 dotted lines) 
 
 
2.0 Severe injury (Continuous lined injury (or)    
 
5-6  dotted injuries) 
3.0 Very severe injury (Several Continuous lined  
 
injuries) 
 
 
 
The Mean Score of each treated group minus Mean Score of control group was 
regarded as the Severity Index of Gastric Mucosal damage. 
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ULCEROGENIC EFFECTS OF SYNTHESIZED COMPOUNDS IN 
 
COMPARISON WITH DICLOFENAC SODIUM. 
 
Table No: 9 
 
 
 
 
 
 
Group Dose (mg/Kg) Ratio of ulcerated 
animals 
Ulcer Index     
(Mean ± SEM) 
I 0.5 ml DMSO 0/6 0.0 ±  0.0 
 
II 30mg/Kg  Diclofenac 
sodium 
6/6 2.1 ± 0.2 
III 5 mg/Kg AS 5/6 1.8 ± 0.3 
 
IV  5 mg/Kg A1S 3/6 0.6 ± 0.1*a
 
V  5 mg/Kg A2S 2/6 0.5 ± 0.1*a
 
VI  5 mg/Kg A3S 4/6 1.9 ± 0.4 
 
VII        5 mg/Kg BS 1/6 0.5 ±0.2 *a
 
VIII 5 mg/Kg B1S 5/6 2.0 ± 0.3 
 
IX 5 mg/Kg B2S 1/6 0.8 ± 0.2*a
 
X 5 mg/Kg B3S 1/6 0.8 ± 0.2*a
 
XI        5 mg/Kg CS 5/6 1.5 ±0.5 
 
XII 5 mg/Kg C1S 5/6 1.6 ± 0.3 
 
XIII 5 mg/Kg C2S 2/6 0.6 ± 0.1*a
 
XIV 5 mg/Kg C3S 2/6 0.6 ± 0.1*a
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Values are expressed as Mean ± SEM. Data analysed by one way ANOVA followed 
by Newman Kevi’s Multiple range test. 
 
*a – Values were significantly different from control at p < 0.01. 
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RESULTS AND DISCUSSION 
 
 
    SYNTHETIC METHODOLOGY: 
 
   The titled compounds were synthesized in a 2 step process: 
 
¾ The first step in which Schiff’s bases of Isatin derivatives were prepared by the 
treatment of 5-nitro Isatin, 5- Chloro Isatin, Isatin with p-Nitro aniline, PABA,    
p-bromo aniline and Sulphanilamide             
 
¾  The Second step was the Mannich Reaction. The presence of active hydrogen in N-1 
position of Isatin facilitates the Mannich reaction. Mannich Bases were prepared by  
treating the Schiff’s Bases of isatin derivatives with Ciprofloxacin in the presence  of  
Formaldehyde. 
 
    Characterization:  
  
¾ The melting points were found in an open end capillary tube method by electrically 
           heating melting point apparatus and are uncorrected. 
¾ The purity of the compounds were analysed by Thin Layer chromatography using  
             Silica Gel (0.5 mm thickness) as stationary phase, employing Chloroform:Methanol   
           (9:1) as Mobile phase, spots were visualized using Iodine vapours. 
           The Rf value of the synthesized compounds were calculated. 
¾ The characterization of the titled compounds including Infrared and Nuclear  
       Magnetic  Resonance Spectral data were in correlation with the expected structure. 
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PHARMACOLOGICAL SCREENING: 
 
Anti Microbial Screening: 
  
¾ Anti Microbial activity of the synthesized compounds were evaluated by Cup and 
Plate method against Staphylococcus aureus, Streptococcus pyogenes, Klebsilla 
aerogenes, Escherichia coli and Candida albicans. 
 
 
       Anti Bacterial Screening: 
 
  
¾  All the Synthesized Compounds Shows significant antibacterial activity against all    
 the four Microorganisms when Compared to the Standard drug Ciprofloxacin. 
 
¾ The Maximum degree of activity was observed against Staphylococcus aureus and 
Streptococcus pyogenes for compounds AS, A1S, A2S, A3S, BS, B1S, B2S, B3S,   
C1S, C2S, C3S. The compound CS shows moderate degree of activity when 
compared to standard drug Ciprofloxacin. 
 
¾ All the Compounds exhibited greater activity against Escherichia coli when 
compared to standard drug Ciprofloxacin. 
 
¾ Moderate Antibacterial activity was observed against Klebsilla aerogenes for all the 
synthesized compounds. 
 
      Anti Fungal Screening: 
 
¾ All the titled compounds showed Moderate activity against the fungi Candida 
albicans. 
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Analgesic Activity: 
 
¾ The synthesized compounds were evaluated for Analgesic Activity by Acetic acid  
 
Induced Writhing Method. 
 
¾ Compounds  AS, A1S, BS, B2S, C2S, and C3S (5mg/kg)posses significant Analgesic 
activity. The writhing effect was significantly inhibited by the above compounds. 
¾ The standard drug Diclofenac Sodium at a dose of 10mg/kg inhibited the writhing  
             effect to a greater extent. 
 
¾ Compounds like A2S, A3S, B1S, B3S, CS and C1S(5mg/kg)  possess moderate 
analgesic activity when compared to standard group. 
 
 Ulcerogenic Index 
 
¾ The Maximum reduction in Ulcerogenic Index (Mean Severity Index ± SEM, n=6) 
was 0.5 ± 0.1 to 0.8 ± 0.2, found in synthesized compounds like  A1S, A2S, BS, B2S, 
B3S, C2S, C3S.  
 
¾ The other synthesized Compounds like AS, A3S, B1S, CS, C1S, Showed high 
severity of Ulcerogenic Index between1.5 to 2.0 equal to the Ulcerogenic index of 
the standard Diclofenac sodium (30mg/Kg) in Group II treated animals.  
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CONCLUSION 
 
 
9 Novel Schiff’s and Mannich Bases of Isatin Derivatives were synthesized by a 2 
step process. 
 
9 The Melting points were found for the synthesized compounds and are uncorrected. 
The purity of the synthesized compounds were analysed by Thin Layer 
Chromatography methods. 
 
9 The structures of the synthesized compounds has been elucidated by Infrared and 
Nuclear Magnetic Resonance Spectroscopy.   
 
9 The Anti Microbial activity of the synthesized compounds were screened by Cup 
and Plate Method against Staphylococcus aureus, Streptococcus pyogenes, 
Escherichia coli, Klebsilla aerogenes and the fungi Candida albicans. 
  
9 All the Compounds Showed maximum activity against Staphylococcus aureus, 
Streptococcus pyogenes, Escherichia coli, and showed Considerable activity against 
Klebsilla aerogenes and the fungi Candida albicans. 
 
9 Based on the results, it become evident that the attachment of various groups like     
p-Nitro aniline, PABA, p-Bromo aniline and Sulphanilamide to isatin nucleus 
along with Ciprofloxacin exhibit greater anti bacterial activity when compared to 
standard drug Ciprofloxacin. 
  
9 The analgesic activity of the synthesized compounds (5mg/kg) were screened by 
Acetic Acid Induced Writhing method in Albino rats against the standard drug 
Diclofenac sodium(25mg/kg) 
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9 From the obtained results the compounds AS, A1S, BS, B2S, C2S, and C3S posses 
significant Analgesic activity. 
 
9 The Ulcerogenic Index of the synthesized compounds was evaluated according to the 
method of Cioli et al. 
 
9 The Maximum reduction in Ulcerogenic Index (Mean Severity Index ± SEM, n=6) 
was 0.5 ± 0.1 to 0.8 ± 0.2, found in synthesized compounds like  A1S, A2S, BS, B2S, 
B3S, C2S, C3S.  
 
9 Though this coverage is not exhaustive, the extended studies on various activities 
such as Anti Convulsant, Anti tumour, Anti Viral etc., and further pharmacological 
characterization of these compounds for host specific actions, toxic side effects and 
drug interactions are needed. Subsequent characterization on these aspects could bring 
these derivatives as successful therapeutic agent.  
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